KR100428601B1 - Bicyclic amino derivatives and prostaglandin di 2 antagonists containing them - Google Patents

Bicyclic amino derivatives and prostaglandin di 2 antagonists containing them Download PDF

Info

Publication number
KR100428601B1
KR100428601B1 KR1019970709573A KR19970709573A KR100428601B1 KR 100428601 B1 KR100428601 B1 KR 100428601B1 KR 1019970709573 A KR1019970709573 A KR 1019970709573A KR 19970709573 A KR19970709573 A KR 19970709573A KR 100428601 B1 KR100428601 B1 KR 100428601B1
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
single bond
phenylene
formula
Prior art date
Application number
KR1019970709573A
Other languages
Korean (ko)
Other versions
KR19990028261A (en
Inventor
미쓰아키 오타니
아키노리 아리무라
다쓰오 쓰리
준지 기시노
쓰네토시 혼마
Original Assignee
시오노기세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노기세이야쿠가부시키가이샤 filed Critical 시오노기세이야쿠가부시키가이샤
Publication of KR19990028261A publication Critical patent/KR19990028261A/en
Application granted granted Critical
Publication of KR100428601B1 publication Critical patent/KR100428601B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/84—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/24—[b,e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5355—Phosphoranes containing the structure P=N-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

하기 화학식 I의 화합물 또는 그의 염 또는 이들의 수화물(예를 들면, (e)의 조건을 갖는 (d) 화합물)은 프로스타글란딘 디2 (PGD2)의 길항제로서 유용하고, 비만 세포의 기능 부전을 포함하는 질병(예: 전신성 비만 세포증 및 전신성 비만 세포 활성화의 장애) 및 기관 수축, 천식, 알러지성 비염, 알러지성 결막염, 두드러기, 허혈성 재관류로 인한 손상을 치료하기 위한 약제 및 항염증제로서 사용할 수 있다. 특히, 코의 폐색증을 치료하는데 유용하다:The compounds of formula (I) or salts thereof or hydrates thereof (e.g., (d) compounds with the conditions of (e)) are useful as antagonists of prostaglandin di2 (PGD 2 ) and include insufficiency of mast cells It can be used as agents and anti-inflammatory agents to treat diseases such as systemic mastocytosis and disorders of systemic mast cell activation, and damage due to organ contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion. In particular, it is useful to treat nasal obstruction:

화학식 IFormula I

상기 식에서,Where

(a)는 (b) 또는 (c)이다.(a) is (b) or (c).

Description

비사이클릭 아미노 유도체 및 이들을 함유하는 프로스타글란딘 D2 길항제Bicyclic amino derivatives and prostaglandin D2 antagonists containing them

본 발명의 일부 비사이클릭 아미노 유도체는 트롬복산 A2(TXA2) 길항제로서 유용하다고 공지되어 있다(일본 특허 공고 공보 제 93-79060 호 참고). 그러나, 일본 특허 공고 공보 제 93-79060 호에서는 상기 화합물이 TXA2길항제로 유용하다고만 기술되어 있고, 본 발명에서 개시하는 바와 같이 PGD2길항제로서의 그의 유용함을 제안하고 있지는 않다.Some bicyclic amino derivatives of the present invention are known to be useful as thromboxane A 2 (TXA 2 ) antagonists (see Japanese Patent Publication No. 93-79060). However, Japanese Patent Publication No. 93-79060 only describes that the compound is useful as a TXA 2 antagonist, and does not suggest its usefulness as a PGD 2 antagonist as disclosed herein.

즉, TXA2는 혈소판 응집 반응, 혈전 형성 등에 대한 작용과 같은 활성을 갖고 있다고 공지되어 있다. 따라서 TXA2길항제는 항혈전제로서 유용하고, 또한 TXA2에 대한 길항 작용에 의한 심근 경색 또는 천식의 치료에 유용하다고 생각되어 왔다.That is, TXA 2 is known to have activities such as action on platelet aggregation reaction, thrombus formation and the like. TXA 2 antagonists are therefore thought to be useful as antithrombotic agents and also for the treatment of myocardial infarction or asthma by antagonistic action on TXA 2 .

한편, 본 발명의 PGD2길항제는 PGD2의 과도한 생성으로 인한 상태를 개선시키는데 유용하다. 특히, 비만 세포의 기능 부전을 포함하는 질병(예: 전신성 비만 세포증 및 전신성 비만 세포 활성화의 장애) 및 기관 수축, 천식, 알러지성 비염, 알러지성 결막염, 두드러기, 허혈성 재관류로 인한 손상 및 염증의 치료용 약제로서 유용하다.On the other hand, the PGD 2 antagonist of the present invention is useful for improving the condition due to excessive production of PGD 2 . In particular, treatment of diseases including dysfunction of mast cells (e.g. systemic mastocytosis and disorders of systemic mast cell activation) and organ contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion and the treatment of inflammation It is useful as a medicament.

상기에서 알 수 있듯이, TXA2길항제 및 PGD2길항제은 활성 부위, 작용 메카니즘 및 용도에 있어서 서로 완전히 상이하고, 매우 상이한 특성을 갖는다. 따라서, 임의의 화합물이 이러한 활성을 동시에 소유하는 것은 예상하지 못했다.It will be appreciated from the above, TXA 2 antagonist and the PGD 2 in gilhangjeeun active site, mechanism of action and use each other completely different, have very different properties. Thus, it was not expected that any compound would simultaneously possess this activity.

PGD2는 면역성 또는 비면역성 자극에 의해 활성화되는 사이클로옥시제네이즈의 작용에 의해 아라키돈산으로부터 PGG2및 PGH2를 거쳐 제조되며, 비만 세포로부터 생성되고 방출되는 중요한 프로스타노이드이다. PGD2는 강력한 여러 생리학적 및 병리학적 활성을 갖는다. 예를 들어, PGD2는 심한 기관 수축의 원인이 되어 기관지 천식을 유발하기도 하고, 전신 알러지 상태에서 말초 혈관으로 퍼져 과민성 쇼크를 유발하기도 한다. 특히 PGD2가 알러지성 비염에서 코 폐색의 개시에 원인이 되는 뜻밖의 물질중의 하나라는 생각에 보다 많은 주의가 집중되어 왔다. 따라서, 코 폐색증을 감소시키기 위한 약제로서 PGD2수용체의 길항물질 또는 PGD2의 생합성에 대한 억제제를 개발하는 것이 제안되었다. 그러나, PGD2생합성의 억제제는 가능하게는 다른 생물체에서의 프로스타글라딘의 합성에 상당한 영향을 미치며, 따라서 PGD2수용체에 특이적인 길항제(차단제)를 개발하는 것이 바람직하다.PGD 2 is produced from arachidonic acid via PGG 2 and PGH 2 by the action of cyclooxygenase activated by immunological or non-immune stimulation and is an important prostanoid produced and released from mast cells. PGD 2 has several potent physiological and pathological activities. For example, PGD 2 can cause severe organ contraction, causing bronchial asthma, and spreading to peripheral blood vessels in systemic allergies, causing irritable shock. In particular, more attention has been paid to the idea that PGD 2 is one of the unexpected substances responsible for the onset of nasal obstruction in allergic rhinitis. Therefore, it has been proposed to develop an antagonist of PGD 2 receptor or an inhibitor for biosynthesis of PGD 2 as a medicament for reducing nasal obstruction. However, inhibitors of PGD 2 biosynthesis possibly have a significant effect on the synthesis of prostagladins in other organisms, and it is therefore desirable to develop antagonists (blockers) specific for the PGD 2 receptor.

발명의 요약Summary of the Invention

본 발명자들은 PGD2수용체에 특이적인 PGD2수용체 길항제(차단제)를 개발하는 것에 대해 집중 연구하여, 하기 화학식 I의 화합물 또는 그의 염이 PGD2수용체 길항제로서 강력한 활성을 가지며 화학적 및 생화학적으로 안정함을 발견하였다.The present inventors Stable has a specific PGD 2 receptor antagonists (blockers) to focus research on developing a compound or a salt thereof, a strong activity as PGD 2 receptor antagonist of formula (I) to PGD 2 receptors by chemical and biochemical Found.

따라서, 본 발명은 활성 성분으로서 하기 화학식 I의 화합물 또는 그의 염 또는 이들의 수화물을 포함하는 PGD2길항제을 제공한다:Accordingly, the present invention provides PGD 2 antagonists comprising as an active ingredient a compound of formula (I) or a salt thereof or a hydrate thereof:

[화학식 I][Formula I]

상기 식에서,Where

은 silver

또는이고,or ego,

A는 선택적으로 쇄중에 헤테로 원자 또는 페닐렌을 함유하고/함유하거나, 옥소기를 함유하고/함유하거나, 불포화 결합을 갖는 알킬렌이고;A is alkylene optionally containing a hetero atom or phenylene in the chain, containing an oxo group and / or having an unsaturated bond;

B는 수소, 알킬, 아르알킬 또는 아실이고;B is hydrogen, alkyl, aralkyl or acyl;

R는 COOR1, CH2OR2또는 CON(R3)R4이고;R is COOR 1 , CH 2 OR 2 or CON (R 3 ) R 4 ;

R1은 수소 또는 알킬이고;R 1 is hydrogen or alkyl;

R2는 수소 또는 알킬이고;R 2 is hydrogen or alkyl;

R3및 R4는 각각 독립적으로 수소, 알킬, 하이드록시 또는 알킬설폰일이고;R 3 and R 4 are each independently hydrogen, alkyl, hydroxy or alkylsulfonyl;

X1은 단일 결합, 페닐렌, 나프틸렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고;X 1 is a single bond, phenylene, naphthylene, thiophendiyl, indoldiyl or oxazoldiyl;

X2는 단일 결합, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-O-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C(Cl)=C(Cl)-, -(CH2)n-, 에티닐렌, -N(R5)-, -N(R51)CO-, -N(R52)SO2-, -N(R53)CON(R54)-, -CON(R55)-, -SO2N(R56)-, -O-, -S-, -SO-, -SO2-, -CO-, 옥사디아졸디일, 티아디아졸디일 또는 테트라졸디일이고;X 2 is a single bond, -N = N-, -N = CH-, -CH = N-, -CH = NN-, -CH = NO-, -C = NNHCSNH-, -C = NNHCONH-, -CH = CH-, -CH (OH)-, -C (Cl) = C (Cl)-,-(CH 2 ) n- , ethynylene, -N (R 5 )-, -N (R 51 ) CO- , -N (R 52 ) SO 2- , -N (R 53 ) CON (R 54 )-, -CON (R 55 )-, -SO 2 N (R 56 )-, -O-, -S-, -SO-, -SO 2- , -CO-, oxadiazolediyl, thiadiazolediyl or tetrazoldiyl;

X3은 알킬, 알켄일, 알킨일, 아릴, 아르알킬, 헤테로사이클릭 기, 사이클로알킬, 사이클로알켄일, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸, -CH=NR6또는 -N=C(R7)R8이고;X 3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl, -CH = NR 6 or -N = C (R 7 ) R 8 ;

R5, R51, R52, R53, R54, R55및 R56은 각각 수소 또는 알킬이고;R 5 , R 51 , R 52 , R 53 , R 54 , R 55 and R 56 are each hydrogen or alkyl;

R6은 수소, 알킬, 하이드록시, 알콕시, 카바모일옥시, 티오카바모일옥시, 우레이도 또는 티오우레이도이고;R 6 is hydrogen, alkyl, hydroxy, alkoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido;

R7및 R8은 각각 독립적으로 알킬, 알콕시 또는 아릴이고;R 7 and R 8 are each independently alkyl, alkoxy or aryl;

n은 1 또는 2이고;n is 1 or 2;

Z는 -SO2- 또는 -CO-이고;Z is -SO 2 -or -CO-;

m은 0 또는 1이며;m is 0 or 1;

이때, 사이클릭 치환체는 니트로, 알콕시, 설파모일, 치환된- 또는 비치환된-아미노, 아실, 아실옥시, 하이드록시, 할로겐, 알킬, 알킨일, 카복시, 알콕시카보닐, 아르알콕시카보닐, 아릴옥시카보닐, 메실옥시, 시아노, 알켄일옥시, 하이드록시알킬, 트리플루오로메틸, 알킬티오, -N=PPh3, 옥소, 티옥소, 하이드록시이미노, 알콕시이미노, 페닐 및 알킬렌디옥시로 구성된 그룹중에서 선택된 1 내지 3개의 치환체를 가질 수도 있다.Wherein the cyclic substituent is nitro, alkoxy, sulfamoyl, substituted- or unsubstituted-amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, alkoxycarbonyl, aryl Oxycarbonyl, mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, -N = PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy It may have 1 to 3 substituents selected from the group consisting of.

본 발명은 비사이클릭 아미노 유도체 및 이들을 함유한 프로스타글란딘 D2(본원 이하에서는 PGD2로 지칭)에 관한 것이다.The present invention relates to bicyclic amino derivatives and prostaglandins D 2 containing them (hereinafter referred to as PGD 2 ).

PGD2길항제로서 사용할 수 있는 화합물의 구체적인 예로는,Specific examples of the compound that can be used as a PGD 2 antagonist include

이이고; this ego;

m이 0이고;m is 0;

Z가 SO2이고;Z is SO 2 ;

X1및 X2가 둘다 단일 결합이고;X 1 and X 2 are both single bonds;

X3이 알킬, 페닐, 나프틸, 스틸릴, 퀴놀릴 또는 티엔일인(이들 치환체중 사이클릭 치환체는 선택적으로 니트로, 알콕시, 치환된- 또는 비치환된-아미노, 할로겐, 알 킬 및 하이드록시알킬로 구성된 그룹중에서 선택된 1 내지 3개의 치환체를 가짐)화학식 I의 화합물 또는 그의 염 또는 이들의 수화물이 있다.Wherein X 3 is alkyl, phenyl, naphthyl, stilyl, quinolyl or thienyl (the cyclic substituents in these substituents are optionally nitro, alkoxy, substituted- or unsubstituted-amino, halogen, alkyl and hydroxyalkyl Having 1 to 3 substituents selected from the group consisting of: (I) or a salt thereof or a hydrate thereof.

유사하게, 구체적인 예로는Similarly, specific examples

가이고; end ego;

m이 1이고,m is 1,

X1및 X2가 둘다 단일 결합이고;X 1 and X 2 are both single bonds;

X3이 신택적으로 할로겐으로 치환된 페닐인 화학식 I의 화합물 또는 그의 염 또는 이들의 수화물이 있다. There is a compound of formula (I), or a salt thereof, or a hydrate thereof, wherein X 3 is phenyl optionally substituted with halogen.

유사하게, 구체적인 예로는Similarly, specific examples

가이고; end ego;

m이 1이고;m is 1;

X1이 페닐이고;X 1 is phenyl;

X2가 -CH2- 또는 -N=N- 이고;X 2 is -CH 2 -or -N = N-;

X3이 페닐인 화학식 I의 화합물 또는 그의 염 또는 이들의 수화물이 있다.Or a salt thereof or a hydrate thereof, wherein X 3 is phenyl.

유사하게, 화학식 I의 화합물의 예로는 하기 화학식 Ia의 화합물 또는 그의 염 또는 이들의 수화물이 있다.Similarly, examples of the compound of formula (I) include the compound of formula (Ia) or salts thereof or hydrates thereof.

[화학식 Ia]Formula Ia

상기 식에서,Where

A, B, R, X1, X2및 X3은 화학식 I에 대하여 정의한 바와 같고,A, B, R, X 1 , X 2 and X 3 are as defined for Formula I,

단, (1) X1및 X2가 단일 결합이고, X3이 치환된- 또는 비치환된-페닐 또는 나프틸인 경우와 (2) A가 5-헵텐일렌이고, R이 COOR1(이때, R1은 수소 또는 메틸임)이고, X1이 1,4-페닐렌이고, X2가 단일 결합이고, X3이 페닐인 경우를 제외한다.Provided that (1) X 1 and X 2 are a single bond, X 3 is substituted- or unsubstituted-phenyl or naphthyl and (2) A is 5-heptenylene and R is COOR 1 (where , R 1 is hydrogen or methyl), X 1 is 1,4-phenylene, X 2 is a single bond and X 3 is phenyl.

유사하게, 화학식 I의 화합물의 예로는 하기 화학식 Ib의 화합물 또는 그의 염 또는 이들의 수화물이 있다:Similarly, examples of the compound of formula (I) include the compound of formula (Ib) or a salt thereof or a hydrate thereof:

[화학식 Ib]Formula Ib

상기 식에서,Where

은또는이고; silver or ego;

A, B, R, X1, X2및 X3은 화학식 I에 대하여 정의한 바와 같고,A, B, R, X 1 , X 2 and X 3 are as defined for Formula I,

단, X1및 X2가 단일 결합이고, X3이 페닐인 경우와, X1이 단일 결합이고, X2가 -O-이고, X3이 벤질인 경우를 제외한다.Except that X 1 and X 2 are a single bond, X 3 is phenyl, X 1 is a single bond, X 2 is —O—, and X 3 is benzyl.

보다 특정하게, 화학식 I의 화합물의 예로는, X1및 X2가 단일 결합이고 X3이 이속사졸릴, 티아디아졸릴, 이소티아졸릴, 모폴릴, 인돌릴, 벤조푸릴, 디벤조푸릴, 디벤조디옥신일, 벤조티엔일, 디벤조티엔일, 카바졸릴, 크산텐일, 페난트리딘일, 디벤즈옥세핀일, 디벤조티에핀일, 시놀일, 크로멘일, 벤즈이미다졸릴 또는 디하이드로벤조티에핀일인 화학식 Ia의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.More specifically, examples of compounds of formula (I) include those wherein X 1 and X 2 are single bonds and X 3 is isoxazolyl, thiadiazolyl, isothiazolyl, morpholyl, indolyl, benzofuryl, dibenzofuryl, di Benzodioxylyl, benzothienyl, dibenzothienyl, carbazolyl, xanthenyl, phenanthridinyl, dibenzoxepinyl, dibenzothienyl, synolyl, chromenyl, benzimidazolyl or dihydrobenzothiene A compound of formula (Ia) or a salt thereof or a hydrate thereof is mentioned.

유사하게, 화학식 I의 화합물의 예로는, X1이 단일 결합이고, X2가 페닐렌이고, X3이 알켄일, 알킨일, -CH=NR6또는 -N=C(R7)R8인 화학식 Ia의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.Similarly, examples of compounds of formula (I) include those wherein X 1 is a single bond, X 2 is phenylene, X 3 is alkenyl, alkynyl, -CH = NR 6 or -N = C (R 7 ) R 8 Phosphorus compounds of formula (Ia) or salts thereof or hydrates thereof.

유사하게, 화학식 I의 화합물의 예로는, R이 COOR1이고, X1이 페닐렌 또는 티오펜디일이고, X2가 단일 결합, -N=N-, -CH=CH-, -CONH-, -NHCO- 또는 에틴일렌이고, X3이 페닐, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸 또는 티엔일인 화학식 Ia의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.Similarly, examples of compounds of formula (I) include those in which R is COOR 1 , X 1 is phenylene or thiophendiyl, X 2 is a single bond, -N = N-, -CH = CH-, -CONH-, A compound of formula (Ia) or a salt thereof or a hydrate thereof, wherein -NHCO- or ethynylene and X 3 is phenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl or thienyl.

보다 특정하게, 본 발명의 화학식 I의 화합물의 예로는가인 화학식 Ib의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다. 보다 바람직한 화합물의 예로는 R이 COOR1(이때 R1은 상기 정의한 것과 같음)인 화학식 Ib의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.More specifically, examples of the compound of formula I of the present invention include end Phosphorus compounds of the formula (Ib) or salts thereof or hydrates thereof are mentioned. Examples of more preferred compounds include compounds of formula (Ib) or salts thereof or hydrates thereof, wherein R is COOR 1, wherein R 1 is as defined above.

유사하게, 화학식 I의 화합물의 예로는, X1이 페닐렌 또는 티오펜디일이고, X2가 단일 결합, -N=N-, -CH=CH-, 에틴일렌, -O-, -S-, -CO-, -CON(R55)-(이때, R55는 상기 정의한 것과 같음), -N(R51)CO-(이때, R51은 상기 정의한 것과 같음)이고, X3이 페닐인 화학식 Ib의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.Similarly, examples of compounds of formula (I) include those in which X 1 is phenylene or thiophendiyl and X 2 is a single bond, -N = N-, -CH = CH-, ethynylene, -O-, -S- , -CO-, -CON (R 55 )-, wherein R 55 is as defined above, -N (R 51 ) CO-, wherein R 51 is as defined above, and X 3 is phenyl Compounds of formula (Ib) or salts thereof or hydrates thereof.

보다 특정하게, 화학식 I의 화합물의 예로는가인 화학식 Ib의 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다. 보다 바람직한 양태의 예로는 B가 수소이고, X1및 X2가 둘다 단일 결합이고, X3이 티엔일, 티아졸릴, 티아디아졸릴, 이소티아졸릴, 피롤일, 피리딜, 벤조푸릴, 벤즈이미다졸릴, 벤조티엔일, 디벤조푸릴, 디벤조티엔일, 퀴놀일 또는 인돌일인 화합물 또는 그의 염또는 이들의 수화물을 들 수 있다. 유사하게, 예로는, X1이 페닐렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고, X2가 단일 결합, -N=N-, -CH=CH-, 에틴일렌, -S- 또는 -O-이고, X3이 아릴 또는 헤테로사이클릭 기인 화합물 또는 그의 염 또는 이들의 수화물을 들 수 있다.More specifically, examples of the compound of formula (I) include end Phosphorus compounds of the formula (Ib) or salts thereof or hydrates thereof are mentioned. Examples of more preferred embodiments include B is hydrogen, X 1 and X 2 are both single bonds, X 3 is thienyl, thiazolyl, thiadizolyl, isothiazolyl, pyrroylyl, pyridyl, benzofuryl, benzimi The compound which is dazolyl, benzothienyl, dibenzofuryl, dibenzothienyl, quinolyl, or indolyl, or its salt or hydrate thereof is mentioned. Similarly, for example, X 1 is phenylene, thiophendiyl, indoldiyl or oxazoldiyl, and X 2 is a single bond, -N = N-, -CH = CH-, ethynylene, -S- or- O-, and X 3 is an aryl or heterocyclic group, or a salt thereof or a hydrate thereof.

상기 화학식 Ia 또는 화학식 Ib의 화합물은 본 발명자들이 합성한 신규 화합물이다.The compound of formula (Ia) or formula (Ib) is a novel compound synthesized by the present inventors.

본 명세서 전체에서 사용되는 용어는 하기에서 정의하는 바와 같다.The terminology used throughout this specification is as defined below.

"알킬렌"이라는 용어는 C1-C9의 직쇄 또는 분지쇄 알킬렌(예: 메틸렌, 메틸메틸렌, 디메틸메틸렌, 메틸에틸메틸렌, 에틸렌, 트리메틸렌, 테트라메틸렌, 펜타메틸렌, 헥사메틸렌, 헵타메틸렌, 옥타메틸렌, 노나메틸렌 등)을 의미한다. 상기 알킬렌은 쇄중에 헤테로 원자(들)(산소, 황, 질소 원자 등) 또는 페닐렌(예: 1,4-페닐렌, 1,3-페닐렌, 1,2-페닐렌 등)을 함유할 수 있고/있거나, 옥소기를 함유할 수있고/있거나, 쇄중의 어느 위치에라도 하나 이상의 이중- 또는 삼중-결합을 가질 수 있다. 예로는, -(CH2)2-O-CH2-, -(CH2)2-O-(CH2)2-, -(CH2)2-O-(CH2)3-, -(CH2)2-O-(CH2)4-, -(CH2)2-O-(CH2)5-, -(CH2)2-O-(CH2)6-, -(CH2)2-S-(CH2)2-, -(CH2)3-S-(CH2)2-, -CH2-S-CH2-, -CH2-S-(CH2)4-, -CH2-N(CH3)-CH2-, -CH2-NH-(CH2)2-, -(CH2)2-N(CH2CH3)-(CH2)3-, -(CH2)2-1,4-페닐렌-CH2-, -(CH2)2-O-1,3-페닐렌-CH2-, -(CH2)2-O-1,2-페닐렌-CH2-, -(CH2)2-O-1,4-페닐렌-CH2-, -CH=CH-S-CH2-1,4-페닐렌-CH2-, -CH=CH-S-CH2-1,3-페닐렌-(CH2)2-, 2-옥소프로필렌-, 3-옥소펜틸렌, 5-옥소헥실렌, 비닐렌, 1-프로펜일렌, 2-프로펜일렌, 1-부텐일렌, 2-부텐일렌, 3-부텐일렌, 1,2-부타디엔일렌, 1,3-부타디엔일렌, 1-펜텐일렌, 2-펜텐일렌, 3-펜텐일렌, 4-펜텐일렌, 1,2-펜타디엔일렌, 1,3-펜타디엔일렌, 1,4-펜타디엔일렌, 2,3-펜타디엔일렌, 2,4-펜타디엔일렌, 1-헥센일렌, 2-헥센일렌, 3-헥센일렌, 4-헥센일렌, 5-헥센일렌, 1,2-헥사디엔일렌, 1,3-헥사디엔일렌, 1,4-헥사디엔일렌, 1,5-헥사디엔일렌, 2,3-헥사디엔일렌, 2,4-헥사디엔일렌, 2,5-헥사디엔일렌, 3,4-헥사디엔일렌, 3,5-헥사디엔일렌, 4,5-헥사디엔일렌, 1,1-디메틸-4-헥센일렌, 1-헵텐일렌, 2-헵텐일렌, 3-헵텐일렌, 4-헵텐일렌, 5-헵텐일렌, 2,2-디메틸-5-헵텐일렌, 6-헵텐일렌, 1,2-헵타디엔일렌, 1,3-헵타디엔일렌, 1,4-헵타디엔일렌, 1,5-헵타디엔일렌, 1,6-헵타디엔일렌, 2,3-헵타디엔일렌, 2,4-헵타디엔일렌, 2,5-헵타디엔일렌, 2,6-헵타디엔일렌, 3,4-헵타디엔일렌, 3,5-헵타디엔일렌, 3,6-헵타디엔일렌, 4,5-헵타디엔일렌, 4,6-헵타디엔일렌 또는 5,6-헵타디엔일렌, 1-프로핀일렌, 3-부틴일렌, 2-펜틴일렌, 5-헥신일렌, 6-헵틴일렌, -(CH2)-CH=CH-O-(CH2)2-, -CH2-S-(CH2)3-, -CH2-시스-CH=CH-1,2-페닐렌-CH2-, -CH=CH-1,4-페닐렌-(CH2)2-, -4-옥소-4,5-헥센일렌 등을 들 수 있다.The term "alkylene" refers to C 1 -C 9 straight or branched chain alkylene, such as methylene, methylmethylene, dimethylmethylene, methylethylmethylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene , Octamethylene, nonamethylene, etc.). The alkylene contains hetero atom (s) (oxygen, sulfur, nitrogen atoms, etc.) or phenylene (eg 1,4-phenylene, 1,3-phenylene, 1,2-phenylene, etc.) in the chain. And / or may contain oxo groups and / or have one or more double- or triple-bonds at any position in the chain. Examples include-(CH 2 ) 2 -O-CH 2 -,-(CH 2 ) 2 -O- (CH 2 ) 2 -,-(CH 2 ) 2 -O- (CH 2 ) 3 -,-( CH 2 ) 2 -O- (CH 2 ) 4 -,-(CH 2 ) 2 -O- (CH 2 ) 5 -,-(CH 2 ) 2 -O- (CH 2 ) 6 -,-(CH 2 ) 2 -S- (CH 2 ) 2 -,-(CH 2 ) 3 -S- (CH 2 ) 2- , -CH 2 -S-CH 2- , -CH 2 -S- (CH 2 ) 4- , -CH 2 -N (CH 3 ) -CH 2- , -CH 2 -NH- (CH 2 ) 2 -,-(CH 2 ) 2 -N (CH 2 CH 3 )-(CH 2 ) 3- , -(CH 2 ) 2 -1,4-phenylene-CH 2 -,-(CH 2 ) 2 -O-1,3-phenylene-CH 2 -,-(CH 2 ) 2 -O-1,2 -Phenylene-CH 2 -,-(CH 2 ) 2 -O-1,4-phenylene-CH 2- , -CH = CH-S-CH 2 -1,4-phenylene-CH 2 -,- CH = CH-S-CH 2 -1,3- phenylene - (CH 2) 2 -, 2- oxo-propylene-3-oxo-pentylene, 5-oxo-cyclohexylene, vinylene, 1-propene ylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene, 1,2-butadieneylene, 1,3-butadieneylene, 1-pentenylene, 2-pentenylene, 3-pentenylene, 4-pentenylene, 1,2-pentadiene ylene, 1,3-pentadiene ylene, 1,4-pentadiene ylene, 2,3-pentadiene ylene, 2,4-pentadiene ylene, 1-hexenylene, 2-hexeneylene, 3-hexene Ethylene, 4-hexelene, 5-hexelene, 1,2-hexadieneylene, 1,3-hexadieneylene, 1,4-hexadieneylene, 1,5-hexadieneylene, 2,3-hexadiene Ylene, 2,4-hexadieneylene, 2,5-hexadielene, 3,4-hexadieneylene, 3,5-hexadielene, 4,5-hexadielene, 1,1-dimethyl-4- Hexenylene, 1-heptenylene, 2-heptenylene, 3-heptenylene, 4-heptenylene, 5-heptenylene, 2,2-dimethyl-5-heptenylene, 6-heptenylene, 1,2-heptadiene Ylene, 1,3-heptadieylene, 1,4-heptadieylene, 1,5-heptadieylene, 1,6-heptadieylene, 2,3-heptadieylene, 2,4-heptadieylene, 2,5-heptadieneylene, 2,6-heptadieylene, 3,4-heptadieneylene, 3,5-heptadieneylene, 3,6-heptadieylene, 4,5-heptadieylene, 4, 6-heptadieneylene or 5,6-heptadieylene, 1-propynylene, 3-butynylene, 2-pentynylene, 5-hexynylene, 6-heptinylene,-(CH 2 ) -CH = CH -O- (CH 2) 2 -, -CH 2 -S- (CH 2) 3 -, -CH 2 - cis -CH = CH-1,2- phenylene -CH 2 -, -CH = CH- 1 , 4-phenylene- (C H 2 ) 2 -,-4-oxo-4,5-hexenylene and the like.

"알킬"이라는 용어는 C1-C20의 직쇄 또는 분지쇄 알킬을 의미하고, 예로는 메틸, 에틸, n-프로필, i-프로필, n-부틸, i-부틸, s-부틸, t-부틸, n-펜틸, i-펜틸, 네오펜틸, t-펜틸, 헥실, 헵틸, 옥틸, 노닐, 데실, 운데실, 도데실, 트리데실, 테트라데실, 펜타데실, 헥사데실, 헵타데실, 옥타데실, 노나데실, 이코실 등을 들 수 있다.The term "alkyl" means C 1 -C 20 straight or branched chain alkyl, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl , n-pentyl, i-pentyl, neopentyl, t-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, Nonadecyl, ecosil etc. are mentioned.

"아릴"이라는 용어는 C6-C14의 모노사이클릭 또는 축합 고리를 의미하고, 예로는 페닐, 나프틸(예: 1-나프틸, 2-나프틸), 안트릴(예: 1-안트릴, 2-안트릴, 9-안트릴), 페난트릴(예: 2-페난트릴, 3-페난트릴, 9-페난트릴), 플루오렌일(예: 2-플루오렌일) 등을 들 수 있다. 페닐이 특히 바람직하다.The term "aryl" refers to a monocyclic or condensed ring of C 6 -C 14 , for example phenyl, naphthyl (eg 1-naphthyl, 2-naphthyl), anthryl (eg 1-an Trilyl, 2-anthryl, 9-anthryl), phenanthryl (e.g. 2-phenanthryl, 3-phenanthryl, 9-phenanthryl), fluorenyl (e.g. 2-fluorenyl), and the like. have. Phenyl is particularly preferred.

"아르알킬"이라는 용어는 알킬중 임의의 치환가능한 위치에서 상기와 같이 정의한 알킬을 상기 아릴로 치환함으로써 형성된 기를 의미한다. 예로는 벤질, 펜에틸, 페닐프로필(예: 3-페닐프로필), 나프틸메틸(예: α-나프틸메틸), 안트릴메틸(예: 9-안트릴메틸), 페난트릴메틸(예: 3-페난트릴메틸) 등을 들 수 있다.The term "aralkyl" means a group formed by substituting alkyl as defined above for aryl at any substitutable position in alkyl. Examples include benzyl, phenethyl, phenylpropyl (e.g. 3-phenylpropyl), naphthylmethyl (e.g. α-naphthylmethyl), anthrylmethyl (e.g. 9-anthrylmethyl), phenanthrylmethyl (e.g. 3-phenanthrylmethyl) etc. are mentioned.

"아실"이라는 용어는 지방족 카복실산으로부터 유도된 C1-C9의 아실을 의미하고, 예로는 포르밀, 아세틸, 프로피온일, 부티릴, 발레릴 등을 들 수 있다.The term "acyl" refers to C 1 -C 9 acyl derived from aliphatic carboxylic acids, including, for example, formyl, acetyl, propionyl, butyryl, valeryl, and the like.

"알킬설폰일"이라는 용어는 설폰일을 상기 알킬로 치환함으로써 형성된 기를 의미하고, 예로는 메틸설폰일, 에틸설폰일, 프로필설폰일 등을 들 수 있다.The term "alkylsulfonyl" refers to a group formed by substituting sulfonyl with said alkyl, and examples thereof include methylsulfonyl, ethylsulfonyl, propylsulfonyl and the like.

"알켄일"이라는 용어는 C2-C20의 직쇄 또는 분지쇄 알켄일을 의미하며 이는 하나 이상의 이중 결합을 함유하는 상기 알킬에 해당된다. 예로는 비닐, 1-프로펜일, 2-프로펜일, 1-부텐일, 2-부텐일, 3-부텐일, 1,2-부타디엔일, 1-펜텐일, 1,2-펜타디엔일, 2-헥센일, 1,2-헥사디엔일, 3-헵텐일, 1,5-헵타디엔일 등을 들 수 있다.The term "alkenyl" refers to a straight or branched chain alkenyl of C 2 -C 20 , which corresponds to the alkyl containing one or more double bonds. Examples include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,2-butadienyl, 1-pentenyl, 1,2-pentadienyl, 2 -Hexenyl, 1,2-hexadienyl, 3-heptenyl, 1,5-heptadienyl, etc. are mentioned.

"알킨일"이라는 용어는 C2-C20의 직쇄 또는 분지쇄 알킨일로서 하나 이상의 삼중 결합을 함유하는 상기 알킬에 해당된다. 예로는, 에틴일, 1-프로핀일, 2-프로핀일, 1-부틴일, 2-부틴일, 3-부틴일 등을 들 수 있다.The term "alkynyl" corresponds to the above alkyl containing one or more triple bonds as straight or branched chain alkynyl of C 2 -C 20 . Examples include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl and the like.

"헤테로사이클릭 기"란 고리상에 산소, 황 및/또는 질소 원자로 구성된 그룹에서 독립적으로 선택된 하나 이상의 헤테로 원자를 함유하는 5원 내지 7원의 사이클릭 고리를 의미하며, 선택적으로 임의의 치환가능한 위치에서 탄소 고리 또는 다른 헤테로사이클릭 기와 축합된다. 예로는, 피롤일(예: 1-피롤일, 3-피롤일), 인돌일(예: 2-인돌일, 3-인돌일, 6-인돌일), 카바졸일(예: 2-카바졸일, 3-카바졸일), 이미다졸일(예: 1-이미다졸일, 4-이미다졸일), 피라졸일(예: 1-피라졸일, 3-피라졸일), 벤즈이미다졸일(예: 2-벤즈이미다졸일, 5-벤즈이미다졸일), 인다졸일(예: 3-인다졸일), 인돌리진일(예: 6-인돌리진일), 피리딜(예: 2-피리딜, 3-피리딜, 4-피리딜), 퀴놀일(예; 8-퀴놀일), 이소퀴놀일(예: 3-이소퀴놀일), 아크리딜(예: 1-아크리딜), 페난트리딘일(예: 2-펜난트리딘일, 3-펜난트리딘일), 피리다진일(예: 3-피리다진일), 피리미딘일(예: 4-피리미딘일), 피라진일(예: 2-피라진일), 시놀린일(예: 3-시놀린일), 프탈라딘일(예: 5-프탈라딘일), 퀴나졸린일(예: 2-퀴나졸린일), 이속사졸일(예: 3-이속사졸일, 4-이속사졸일), 벤즈이속사졸일(예: 1,2-벤즈이속사졸-4-일, 2,1-벤즈이속사졸-3-일), 옥사졸일(예: 2-옥사졸일, 4-옥사졸일, 5-옥사졸일), 벤즈옥사졸일(예: 2-벤즈옥사졸일), 벤즈옥사디아졸일(예: 4-벤즈옥사디아졸일), 이소티아졸일(예: 3-이소티아졸일, 4-이소티아졸일), 벤즈이소티아졸일(예: 1,2-벤즈이소티아졸-3-일, 2,1-벤즈이소티아졸-5-일), 티아졸일(에 : 2-티아졸일), 벤조티아졸일(예: 2-벤조티아졸일), 티아디아졸일(에: 1,2,3-티아디아졸-4-일), 옥사디아졸일(예: 1,3,4-옥사디아졸-2-일), 디하이드로옥사디아졸일(예: 4,5-디하이드로-1,2,4-옥사디아졸-3-일), 푸릴(예: 2-푸릴, 3-푸릴), 벤조푸릴(예: 3-벤조푸릴), 이소벤조푸릴(예: 1-이소벤조푸릴), 티엔일(예: 2-티엔일, 3-티엔일), 벤조티엔일(예: 1-벤조티오펜-2-일, 2-벤조티오펜-1-일), 테트라졸일(예: 5-테트라졸일), 벤조디옥솔일(예: 1,3-벤조디옥솔-5-일), 디벤조푸릴(예: 2-디벤조푸릴, 3-디벤조푸릴), 디벤즈옥세핀일(예: 디벤즈[b,f]옥세핀-2-일), 디하이드로디벤즈옥세핀일(예: 디하이드로디벤즈[b,f]옥세핀일-2-일), 크로멘일(예: 2H-크로멘-3-일, 4H-크로멘-2-일), 디벤조티에핀일(예: 디벤조[b,f]티에핀-3-일, 디하이드로디벤조[b,f]티에핀-3-일), 모폴린일(예: 1,4-몰포린-4-일), 페노티아딘일(2-페노티아딘일), 사이클로펜타티엔일(예: 사이클로펜타[b]티오펜-3-일), 사이클로헥사티엔일(예: 사이클로헥사[b]티오펜-3-일), 디벤조티엔일(예: 2-디벤조티엔일), 디벤조피란일(예: 2-디벤조피란일), 디벤조-p-디옥실(예: 2-디벤조-p-디옥실) 등을 들 수 있다."Heterocyclic group" means a 5-7 membered cyclic ring containing one or more heteroatoms independently selected from the group consisting of oxygen, sulfur and / or nitrogen atoms on the ring, optionally optionally substituted In position condensed with a carbon ring or other heterocyclic group. Examples include pyrrolyl (e.g. 1-pyrrolyl, 3-pyrrolyl), indolyl (e.g. 2-indolyl, 3-indolyl, 6-indolyl), carbazolyl (e.g. 2-carbazolyl, 3-carbazolyl), imidazolyl (e.g. 1-imidazolyl, 4-imidazolyl), pyrazolyl (e.g. 1-pyrazolyl, 3-pyrazolyl), benzimidazolyl (e.g. 2- Benzimidazolyl, 5-benzimidazolyl), indazolyl (e.g. 3-indazolyl), indolizinyl (e.g. 6-indolizinyl), pyridyl (e.g. 2-pyridyl, 3-pyridine) Dill, 4-pyridyl), quinolyl (eg 8-quinolyl), isoquinolyl (eg 3-isoquinolyl), acridil (eg 1-acridyl), phenanthridinyl (eg 2-phennantridinyl, 3-phenanthridinyl), pyridazinyl (e.g. 3-pyridazinyl), pyrimidinyl (e.g. 4-pyrimidinyl), pyrazinyl (e.g. 2-pyrazinyl) , Cynolinyl (e.g. 3-shinolinyl), phthalazinyl (e.g. 5-phthaladinyl), quinazolinyl (e.g. 2-quinazolinyl), isoxazolyl (e.g. 3-isoxazole) 1, 4-isoxazolyl), benzisoxazolyl (e.g. 1,2-benzisoxazol-4- , 2,1-benzisoxazol-3-yl), oxazolyl (eg 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), benzoxazolyl (eg 2-benzoxazolyl), benzoxa Diazolyl (e.g. 4-benzoxadiazolyl), isothiazolyl (e.g. 3-isothiazolyl, 4-isothiazolyl), benzisothiazolyl (e.g. 1,2-benzisothiazol-3- 1,2,1-benzisothiazol-5-yl), thiazolyl (e.g. 2-thiazolyl), benzothiazolyl (e.g. 2-benzothiazolyl), thiadiazolyl (e.g. 1,2, 3-thiadiazol-4-yl), oxadiazolyl (eg 1,3,4-oxadiazol-2-yl), dihydrooxadiazolyl (eg 4,5-dihydro-1,2 , 4-oxadiazol-3-yl), furyl (e.g. 2-furyl, 3-furyl), benzofuryl (e.g. 3-benzofuryl), isobenzofuryl (e.g. 1-isobenzofuryl), thiene One (e.g. 2-thienyl, 3-thienyl), benzothienyl (e.g. 1-benzothiophen-2-yl, 2-benzothiophen-1-yl), tetrazolyl (e.g. 5-tetra Zolyl), benzodioxolyl (e.g. 1,3-benzodioxol-5-yl), dibenzofuryl (e.g. 2- Benzofuryl, 3-dibenzofuryl), dibenzoxepinyl (e.g. dibenz [b, f] oxepin-2-yl), dihydrodibenzoxepinyl (e.g. dihydrodibenz [b, f] Oxepinyl-2-yl), chromaenyl (e.g. 2H-chromen-3-yl, 4H-chromen-2-yl), dibenzothiepinyl (e.g. dibenzo [b, f] thiepin-3 -Yl, dihydrodibenzo [b, f] thiin-3-yl), morpholinyl (eg 1,4-morpholin-4-yl), phenothiadinyl (2-phenothiadinyl), cyclo Pentathienyl (eg cyclopenta [b] thiophen-3-yl), cyclohexathienyl (eg cyclohexa [b] thiophen-3-yl), dibenzothienyl (eg 2-dibenzo Thienyl), dibenzopyranyl (eg 2-dibenzopyranyl), dibenzo-p-dioxyl (eg 2-dibenzo-p-dioxyl), and the like.

"사이클로알킬"이라는 용어는 C3-C8의 사이클릭 알킬을 의미하고, 예로는 사이클로프로필, 사이클로부틸, 사이클로펜틸, 사이클로헥실 등을 들 수 있다.The term "cycloalkyl" means C 3 -C 8 cyclic alkyl, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

"사이클로알켄일"이라는 용어는 C3-C8의 사이클릭 알켄일을 의미하고, 예로는 사이클로프로펜일(예: 1-사이클로프로펜일), 사이클로부텐일(예: 2-사이클로부텐-1-일), 사이클로펜텐일(1-사이클로펜텐-1-일), 사이클로헥센일(예: 1-사이클로헥센-1-일) 등을 들 수 있다.The term "cycloalkenyl" refers to a cyclic alkenyl of C 3 -C 8 , for example cyclopropenyl (eg 1-cyclopropenyl), cyclobutenyl (eg 2-cyclobuten-1- 1), cyclopentenyl (1-cyclopenten- 1-yl), cyclohexenyl (for example, 1-cyclohexen-1-yl), etc. are mentioned.

"알콕시"라는 용어는 C1-C6의 알콕시를 의미하고, 예로는 메톡시, 에톡시, n-프로폭시, i-프로폭시, n-부톡시 등을 들 수 있다.The term "alkoxy" means C 1 -C 6 alkoxy, and examples thereof include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and the like.

"치환된- 또는 비치환된-아미노"라는 정의에 있어서 치환된 아미노의 예로는 단일- 또는 이-치환된 아미노(예: 메틸아미노, 에틸아미노, 디메틸아미노, 사이클로헥실아미노, 페닐아미노, 디페닐아미노) 또는 사이클릭 아미노(예: 피페리디노, 피페라디노 또는 모폴리노)를 들 수 있다.Examples of substituted amino in the definition of "substituted- or unsubstituted-amino" include mono- or di-substituted amino (eg, methylamino, ethylamino, dimethylamino, cyclohexylamino, phenylamino, diphenyl). Amino) or cyclic amino such as piperidino, piperadino or morpholino.

"아실옥시"라는 용어는 상기 "아실"로부터 유도된 아실옥시를 의미하고, 예로는 아세틸옥시, 프로피온일옥시, 부티릴옥시, 발레릴옥시 등을 들 수 있다.The term "acyloxy" means acyloxy derived from "acyl", and examples thereof include acetyloxy, propionyloxy, butyryloxy, valeryloxy and the like.

"할로겐"이라는 용어는 불소, 염소, 브롬 및 요오드를 의미한다.The term "halogen" means fluorine, chlorine, bromine and iodine.

"알콕시카보닐"이라는 용어는 상기 "알콕시"로부터 유도된 알콕시카보닐 기를 의미하고, 예로는 메톡시카보닐, 에톡시카보닐, 페닐옥시카보닐 등을 들 수 있다.The term "alkoxycarbonyl" refers to an alkoxycarbonyl group derived from "alkoxy", and examples thereof include methoxycarbonyl, ethoxycarbonyl, phenyloxycarbonyl and the like.

"아르알킬옥시카보닐"이라는 용어는 상기 "아르알킬"로부터 유도된 아르알킬옥시카보닐 기를 의미하고, 예로는 벤질옥시카보닐, 펜에틸옥시카보닐 등을 들 수 있다.The term "aralkyloxycarbonyl" refers to an aralkyloxycarbonyl group derived from "aralkyl", and examples thereof include benzyloxycarbonyl, phenethyloxycarbonyl and the like.

"아릴옥시카보닐"이라는 용어는 상기 "아릴"로부터 유도된 아릴옥시카보닐기를 의미하고, 예로는 페닐옥시카보닐, 나프틸옥시카보닐 등을 의미한다.The term "aryloxycarbonyl" refers to an aryloxycarbonyl group derived from "aryl", for example, phenyloxycarbonyl, naphthyloxycarbonyl and the like.

"알켄일옥시"라는 용어는 상기 "알켄일"로부터 유도된 알켄일옥시기를 의미하고, 예를 들면 비닐옥시, 1-프로펜일옥시, 2-부텐일옥시 등을 들 수 있다.The term "alkenyloxy" refers to an alkenyloxy group derived from "alkenyl", and examples thereof include vinyloxy, 1-propenyloxy, 2-butenyloxy and the like.

"하이드록시알킬"이라는 용어는 상기 "알킬"로부터 유도된 하이드록시알킬기를 의미하고, 예로는 하이드록시메틸, 하이드록시에틸, 하이드록시프로필 등을 들 수 있다.The term "hydroxyalkyl" means a hydroxyalkyl group derived from "alkyl", and examples thereof include hydroxymethyl, hydroxyethyl, hydroxypropyl and the like.

"알킬티오"라는 용어는 상기 "알킬"로부터 유도된 알킬티오기를 의미하고, 예로는 메틸티오, 애틸티오, 프로필티오 등을 들 수 있다.The term "alkylthio" means an alkylthio group derived from "alkyl", and examples thereof include methylthio, attylthio, propylthio and the like.

"알킬렌디옥시"라는 용어는 C1-C3의 알킬렌디옥시를 의미하고, 예로는 매틸렌디옥시, 에틸렌디옥시, 프로필렌디옥시 등을 들 수 있다.The term " alkylenedioxy " means an alkylenedioxy of C 1 -C 3 , and examples thereof include methylenedioxy, ethylenedioxy, propylenedioxy and the like.

"페닐렌", "나프틸렌", "티오펜디일", "인돌디일", "옥사졸디일", "옥사디아졸디일" 및 "테트라졸디일"의 경우, 상기 기는 임의의 두 치환가능한 부위에서 이웃하는 기에 결합될 수 있다.In the case of "phenylene", "naphthylene", "thiophendiyl", "indoldiyl", "oxazoldiyl", "oxadiazolediyl" and "tetrazoldiyl", the group is any two substitutable moiety. It can be bonded to neighboring groups in.

상기 정의에서, 치환체가 사이클릭인 경우, 니트로, 알콕시, 설파모일, 치환된- 또는 비치환된-아미노, 아실, 아실옥시, 하이드록시, 할로겐, 알킬, 알킨일, 카복시, 알콕시카보닐, 아르알콕시카보닐, 아릴옥시카보닐, 메실옥시, 시아노, 알켄일옥시, 하이드록시알킬, 트리플루오로메틸, 알킬티오, N=PPh3, 옥소, 티옥소, 하이드록시이미노, 알콕시이미노, 페닐 및 알킬렌디옥시중에서 선택된 1 내지 3개의 치환체로 치환될 수도 있다. 치환체는 고리상의 임의의 치환가능한 위치에 결합될 수도 있다.In the above definition, when the substituent is cyclic, nitro, alkoxy, sulfamoyl, substituted- or unsubstituted-amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, ar Alkoxycarbonyl, aryloxycarbonyl, mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, N = PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and It may also be substituted with 1 to 3 substituents selected from alkylenedioxy. Substituents may be bonded at any substitutable position on the ring.

화학식 I의 염의 예로는 알칼리 금속(예: 리튬, 나트륨 또는 칼륨), 알칼리 토금속(예: 칼슘), 유기 염기(예: 트로메트아민, 트리메틸아민, 트리에틸아민, 2-아미노부탄, t-부틸아민, 디이소프로필에틸아민, n-부틸메틸아민, 사이클로헥실아민, 디사이클로헥실아민, N-이소프로필사이클로헥실아민, 푸르푸릴아민, 벤질아민, 메틸벤질아민, 디벤질아민, N,N-디메틸벤질아민, 2-클로로벤질아민, 4-메톡시벤질아민, 1-나프틸렌메틸아민, 디페닐벤질아민, 트리페닐아민, 1-나프틸아민, 1-아미노안트라센, 2-아미노안트라센, 디하이드로아비에틸아민, N-메틸모폴린 또는 피리딘), 아미노산(예: 리신 또는 아르기닌) 등으로 형성된 염을 들 수 있다.Examples of salts of formula (I) include alkali metals such as lithium, sodium or potassium, alkaline earth metals such as calcium, organic bases such as trometamine, trimethylamine, triethylamine, 2-aminobutane, t-butyl Amine, diisopropylethylamine, n-butylmethylamine, cyclohexylamine, dicyclohexylamine, N-isopropylcyclohexylamine, furfurylamine, benzylamine, methylbenzylamine, dibenzylamine, N, N- Dimethylbenzylamine, 2-chlorobenzylamine, 4-methoxybenzylamine, 1-naphthylenemethylamine, diphenylbenzylamine, triphenylamine, 1-naphthylamine, 1-aminoanthracene, 2-aminoanthracene, di Hydroabiethylamine, N-methylmorpholine or pyridine), amino acids such as lysine or arginine, and the like.

"수화물"이라는 용어는 화학식 I의 화합물 또는 그의 염의 수화물을 의미한다. 예로는 일- 및 이-수화물을 들 수 있다.The term "hydrate" means a hydrate of the compound of formula (I) or salt thereof. Examples include mono- and di-hydrates.

본 발명의 화합물은 화학식 I로 표현되고 입체 이성질체(예: 부분입체 이성질체, 에피머, 거울상 이성질체) 및 라세미 화합물의 임의의 유형을 포함한다.Compounds of the present invention are represented by Formula I and include stereoisomers (eg diastereomers, epimers, enantiomers) and any type of racemic compound.

화학식 I의 화합물 중, m=1인 화합물, 특히 하기 표 3b 및 표 3c에서 제시한 화합물은 일본 특허 공개 공보 제 90-180862호에서 기술된 공지의 화합물이다.Among the compounds of the formula (I), compounds in which m = 1, in particular the compounds shown in Tables 3b and 3c below, are known compounds described in Japanese Patent Application Laid-open No. 90-180862.

화학식 I의 화합물 중, m=0인 화합물(하기 일반식(I')로 표현된 화합물)은 하기 일반식(II)의 아미노 화합물을, 부분 구조가 하기 Z-X1-X2-X3에 상응하는 설폰산 또는 카복실산의 반응성 유도체와 반응시켜 제조할 수 있다:Among the compounds of the formula (I), the compound having m = 0 (a compound represented by the following general formula (I ′)) corresponds to an amino compound of the general formula (II), wherein the partial structure corresponds to the following ZX 1 -X 2 -X 3 It can be prepared by reacting with a reactive derivative of sulfonic acid or carboxylic acid.

상기 식에서, A, B, R, X1, X2, X3, Y 및 Z는 상기 정의한 것과 같다.Wherein A, B, R, X 1 , X 2 , X 3 , Y and Z are as defined above.

부분 구조가 Z-X1-X2-X3에 상응하는 설폰산은 일반식 X3-X2-X1-SO2OH의 화합물이고, 상기 부분 구조에 상응하는 카복실산은 일반식 X3-X2-X1-COOH의 화합물이다. 이러한 설폰산 또는 카복실산의 반응성 유도체는 상응하는 할라이드(예: 클로라이드, 브로마이드, 요오다이드), 산 무수물(예: 포름산 또는 아세트산의 혼합된 산 무수물), 활성 에스테르(예: 숙신이미드 에스테르)를 의미하고, 그 예로는 일반적으로 아미노기의 아실화에 사용되는 아실화제를 들 수 있다. 카복실산(X3-X2-X1-COOH)은 아민과 카복실산의 축합 반응에서 사용되는 축합제(예:디사이클로헥실카보디이미드(DCC), 1-에틸-3-(3-디메틸아미노프로필)카보디이미드, N,N'-카보닐디이미다졸의 존재하에 이를 반응성 유도체로 변환시키지 않고 그대로 반응에 사용할 수 있다.Sulphonic acids whose partial structure corresponds to ZX 1 -X 2 -X 3 are compounds of the general formula X 3 -X 2 -X 1 -SO 2 OH, and the carboxylic acid corresponding to the partial structure is of the general formula X 3 -X 2- . X 1 -COOH compound. Such reactive derivatives of sulfonic acids or carboxylic acids can be prepared by the corresponding halides (e.g. chlorides, bromide, iodide), acid anhydrides (e.g. mixed acid anhydrides of formic acid or acetic acid), active esters (e.g. succinimide esters) Examples thereof include acylating agents generally used for acylation of amino groups. Carboxylic acids (X 3 -X 2 -X 1 -COOH) are condensing agents used in condensation reactions of amines and carboxylic acids (e.g. dicyclohexylcarbodiimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) ) Carbodiimide, N, N'-carbonyldiimidazole can be used in the reaction as it is without converting it into a reactive derivative.

상기 반응은 아미노기의 아실화에 일반적으로 사용되는 조건하에서 수행될 수 있다. 예로는 할라이드 산을 사용하는 축합의 경우에, 에테르 용매(예: 디에틸에테르, 테트라하이드로푸란, 디옥산), 벤젠 용매(예: 벤젠, 톨루엔, 크실렌), 할로겐화된 탄화수소 용매(예: 디클로로메탄, 디클로로에탄, 클로로포름), 에틸 아세테이트, 디메틸포름아미드, 디메틸 설폭사이드, 아세토니트릴 등과 같은 용매를 사용하여, 필요하다면 염기(예컨대, 유기 염기(예: 트리에틸아민, 피리딘, N,N-디메틸아미노피리딘, N-메틸모폴린), 무기 염기(예: 나트륨 하이드록사이드, 칼륨 하이드록사이드, 칼륨 카보네이트 등))의 존재하에 실온에서, 냉각하면서 또는 바람직하게는 -20℃ 내지 냉각하의 온도에서 또는 실온 내지 반응계의 환류 온도에서 가열하면서, 수 분 또는 수 시간동안, 바람직하게는 0.5 시간 내지 24시간, 보다 바람직하게는 1 시간 내지 12시간동안 수행된다.The reaction can be carried out under the conditions generally used for acylation of amino groups. Examples of condensation using halide acids include ether solvents (e.g. diethyl ether, tetrahydrofuran, dioxane), benzene solvents (e.g. benzene, toluene, xylene), halogenated hydrocarbon solvents (e.g. dichloromethane) , Solvents such as dichloroethane, chloroform), ethyl acetate, dimethylformamide, dimethyl sulfoxide, acetonitrile and the like, if necessary, using a base (e.g., an organic base such as triethylamine, pyridine, N, N-dimethylamino Pyridine, N-methylmorpholine), inorganic bases (e.g. sodium hydroxide, potassium hydroxide, potassium carbonate, etc.)) at room temperature, with cooling or preferably at temperatures between -20 ° C and cooling or Heating from room temperature to reflux of the reaction system, for several minutes or hours, preferably for 0.5 to 24 hours, more preferably for 1 to 12 hours It is a row.

다른 반응성 유도체 또는 유리 산과 아민(II)의 반응을 위한 반응 조건은 반응성 유도체 또는 유리 산의 각각의 특징에 따라 통상의 방식으로 결정할 수 있다.The reaction conditions for the reaction of the other reactive derivative or free acid with the amine (II) can be determined in a customary manner according to the respective characteristics of the reactive derivative or free acid.

반응 생성물은 통상의 정제 방법, 예를 들어, 용매로의 추출, 크로마토그래피, 재결정화 등에 의해 정제할 수 있다.The reaction product can be purified by conventional purification methods such as extraction with a solvent, chromatography, recrystallization and the like.

본 발명의 방법의 출발 물질인 화합물(II)의 구체적인 예는 다음과 같다. 3-아미노[2.2.1]비사이클릭 화합물의 예로는 7-(3-아미노비사이클로[2.2.1]헵트-2-일)-5-헵텐산, 7-(3-아미노비사이클로[2.2.1]헵트-2-일)-2,2-디메틸-5-헵텐산, 7-(N-메틸-3-아미노비사이클로[2.2.1]헵트-2-일)-5-헵텐산, 6-(3-아미노비사이클로[2.2.1]헵트-2-일)-5-헥센산을 들 수 있다. 2-아미노-6,6-디메틸[3.1.1]비사이클릭 화합물의 구체적인 예로는 7-(2-아미노-6,6-디메틸비사이클로[3.1.1]헵트-3-일)-5-헵텐산을 들 수 있다. 이러한 출발 물질에서, 헵텐산 쇄를 포화시켜 헵탄산 쇄를 형성할 수도 있고, 쇄중에 헤테로 원자(들) 또는 헤테로기(들)(예: -O-, -S-, -NH- 또는 페닐렌)를 포함할 수도 있거나, 옥소기로 치환될 수도 있다. 이러한 화합물의 예로는 7-(3-아미노비사이클로[2 2.1]헵트-2-일)헵탄산, 4-[2-(2-아미노비사이클로[3.3.1]헵트-3-일)에톡시페닐아세트산, 7-(3-아미노비사이클로[2.2.1]헵트-2-일)-6-옥소-헵탄산을 들 수 있다. 이러한 출발 물질은 일본 특허 공고 공보 제 93-79060 호 또는 제 91-23170 호에 기술되어 있거나 또는 본원에 기술되어 있는 방법에 따라 제조할 수 있다.Specific examples of compound (II) which is a starting material of the process of the present invention are as follows. Examples of 3-amino [2.2.1] bicyclic compounds include 7- (3-aminobicyclo [2.2.1] hept-2-yl) -5-heptenic acid, 7- (3-aminobicyclo [2.2 .1] hept-2-yl) -2,2-dimethyl-5-heptenic acid, 7- (N-methyl-3-aminobicyclo [2.2.1] hept-2-yl) -5-heptenic acid, 6- (3-aminobicyclo [2.2.1] hept-2-yl) -5-hexenoic acid. Specific examples of 2-amino-6,6-dimethyl [3.1.1] bicyclic compounds include 7- (2-amino-6,6-dimethylbicyclo [3.1.1] hept-3-yl) -5- Heptenoic acid. In such starting materials, heptenoic acid chains may be saturated to form heptanoic acid chains, and heteroatomic (s) or heterogroup (s) in the chain, such as -O-, -S-, -NH- or phenylene ) Or may be substituted with an oxo group. Examples of such compounds include 7- (3-aminobicyclo [2 2.1] hept-2-yl) heptanoic acid, 4- [2- (2-aminobicyclo [3.3.1] hept-3-yl) ethoxy Phenylacetic acid and 7- (3-aminobicyclo [2.2.1] hept-2-yl) -6-oxo-heptanoic acid. Such starting materials can be prepared according to the methods described in or disclosed herein in Japanese Patent Publication Nos. 93-79060 or 91-23170.

상기 부분 구조(Z-X1-X2-X3)에 상응하는 설폰산(X3-X2-X1-SO2OH) 및 카복실산(X3-X2-X1-COOH)은 상기 X에 상응하는 치환체를 갖는 설폰산 또는 카복실산을 의미한다. 즉, 예로는 알칸-설폰산 또는 -카복실산, 알켄-설폰산 또는 -카복실산, 알킨-설폰산 또는 -카복실산, 사이클로알칸-설폰산 또는 -카복실산, 사이클로알켄-설폰산 또는 -카복실산, 아릴-설폰산 또는 -카복실산, 아르알킬옥시-설폰산 또는 - 카복실산, 헤테로사이클릭 치환된-설폰산 또는 -카복실산, 헤테로아릴알킬-설폰산 또는 -카복실산 및 치환된-아미노-설폰산 또는 -카복실산을 들 수 있다. 설폰산 또는 카복실산은 각각 상기 치환체(들)를 가질 수도 있다. 이러한 설폰산 및 카복실산은 시판중이나 또는 공지된 방법에 따라 공지된 화합물로부터 쉽게 합성할 수 있다. 반응하자마자, 설폰산 또는 카복실산은 필요한 경우, 상기 상응하는 반응성 유도체로 변환될 수 있다. 예를 들어, 산 할라이드가 필요한 경우, 문헌[Shin-Jikken-Kagaku-Koza, vol. 14, 1787 페이지 (1978); Synthesis, 854-854(1986), Shin-Jikken-Kagaku-Koza, vol. 22, 115 페이지 (1992)]에서 기술하는 바와 같은 공지된 방법에 따라 화합물을 티온일 할라이드(예: 티온일 클로라이드), 인 할라이드(예: 삼염화인, 오염화인) 또는 옥살릴 할라이드(예: 옥살릴 클로라이드)와 반응시킨다. 다른 반응성 유도체 또한 공지된 방법으로 제조될 수 있다.Sulphonic acid (X 3 -X 2 -X 1 -SO 2 OH) and carboxylic acid (X 3 -X 2 -X 1 -COOH) corresponding to the partial structure (ZX 1 -X 2 -X 3 ) are added to X. By sulfonic acid or carboxylic acid with the corresponding substituents is meant. That is, for example, alkane-sulfonic acid or -carboxylic acid, alkene-sulfonic acid or -carboxylic acid, alkyne-sulfonic acid or -carboxylic acid, cycloalkane-sulfonic acid or -carboxylic acid, cycloalkene-sulfonic acid or -carboxylic acid, aryl-sulfonic acid Or -carboxylic acid, aralkyloxy-sulfonic acid or -carboxylic acid, heterocyclic substituted-sulfonic acid or -carboxylic acid, heteroarylalkyl-sulfonic acid or -carboxylic acid and substituted-amino-sulfonic acid or -carboxylic acid. . The sulfonic acid or carboxylic acid may each have the above substituent (s). Such sulfonic acids and carboxylic acids are commercially available or can be readily synthesized from known compounds according to known methods. Upon reaction, the sulfonic acid or carboxylic acid can be converted to the corresponding reactive derivative, if necessary. For example, when acid halides are required, see Shin-Jikken-Kagaku-Koza, vol. 14, 1787 page (1978); Synthesis, 854-854 (1986), Shin-Jikken-Kagaku-Koza, vol. 22, p. 115 (1992), according to known methods, the compounds may be treated with thionyl halides (e.g. thionyl chloride), phosphorus halides (e.g. phosphorus trichloride, phosphorus pentachloride) or oxalyl halides (e.g. jade With salyl chloride). Other reactive derivatives can also be prepared by known methods.

목적하는 화학식 I의 화합물중에서, 측쇄 A가 불포화 결합, 특히 이중 결합을 함유하는 화합물은 하기 일반식(III)의 알데하이드 유도체를 측쇄 A-R의 나머지 부분에 상응하는 일라이드 화합물과 비티히(Wittig) 반응 조건하에서 반응시켜 제조할 수 있다:Among the compounds of the formula (I) of interest, compounds in which the side chain A contains an unsaturated bond, in particular a double bond, react with the Wittig reaction of an aldehyde derivative of the general formula (III) It can be prepared by reacting under conditions:

상기 식에서, A, B, R, X1, X2, X3, Y 및 Z는 상기 정의한 바와 같다.Wherein A, B, R, X 1 , X 2 , X 3 , Y and Z are as defined above.

출발 화합물(III)은 예를 들어 일본 특허 공개 공보 제 90-256650호에 기술된 방법에 따라 제조될 수 있다. 또한, 측쇄 A-R의 나머지 부분에 상응하는 일라이드 화합물은, 트리페닐포스핀을 상응하는 할로겐화된 알칸산 또는 그의 에스테르 유도체, 에테르 유도체 또는 아미드 유도체와 공지된 방법에 따라 염기의 존재하에서 반응시켜 합성할 수 있다.Starting compound (III) can be prepared according to the method described, for example, in Japanese Patent Laid-Open No. 90-256650. In addition, the lide compounds corresponding to the rest of the side chain AR can be synthesized by reacting triphenylphosphine with the corresponding halogenated alkanoic acid or its ester derivative, ether derivative or amide derivative in the presence of a base according to a known method. Can be.

목적하는 화학식 I의 화합물중에서, R이 COOH인 화합물은 바람직한 경우 상응하는 에스테르 유도체, 알콜 유도체, 에테르 유도체, 아미드 유도체로 전환될 수 있다. 예를 들어, 에스테르 유도체는 카복실산을 종래의 방법으로 에스테르화하여 제조할 수 있다. 에스테르 유도체는 환원되는 경우, 알콜 유도체를 형성하고, 아미드화되는 경우, 아미드 유도체를 형성한다. 에테르 유도체는 알콜 유도체를 O-알킬화시켜 수득할 수 있다.Of the compounds of formula (I) of interest, compounds in which R is COOH can be converted, if desired, to the corresponding ester derivatives, alcohol derivatives, ether derivatives, amide derivatives. For example, ester derivatives can be prepared by esterifying carboxylic acids by conventional methods. The ester derivative, when reduced, forms an alcohol derivative and, when amidated, forms an amide derivative. Ether derivatives can be obtained by O-alkylating alcohol derivatives.

본 발명의 화학식 I의 화합물은, PGD2수용체에 결합됨으로써 시험관내에서 PGD2에 대한 길항 효과를 나타내고, PGD2의 과다한 생성으로 인한 비만 세포의 기능 부전과 관련된 질병을 치료하기 위한 약제로서 유용하다. 예를 들어, 화학식 I의 화합물은 전신성 비만 세포증 및 전신성 비만 세포 활성화의 장애 및 기관 수축, 천식, 알러지성 비염, 알러지성 결막염, 두드러기, 허혈성 재관류로 인한 손상 및 염증과 같은 질병을 치료하기 위한 약제로서 유용하다. 화학식 I의 화합물은 생체내에서 코의 폐색증에 대해 예방 효과를 보이고, 따라서 그를 치료하는 약제로서 특히 유용하다.The compounds of formula (I) of the present invention exhibit an antagonistic effect on PGD 2 in vitro by binding to the PGD 2 receptor and are useful as a medicament for treating diseases associated with dysfunction of mast cells due to excessive production of PGD 2 . . For example, the compounds of formula (I) are agents for treating systemic mastocytosis and disorders of systemic mast cell activation and diseases such as organ contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, damage and inflammation due to ischemic reperfusion. Useful as Compounds of formula (I) have a prophylactic effect against nasal obstruction in vivo and are therefore particularly useful as agents for treating them.

치료에 본 발명의 화학식 I의 화합물을 사용하는 경우, 화합물은 경구 및 비경구 투여를 위한 일반적인 제형으로 제형화될 수 있다. 본 발명의 화학식 I의 화합물을 함유하는 약학 조성물은 경구 및 비경구 투여를 위한 형태일 수 있다. 특히, 상기 화합물은 정제, 캡슐, 과립, 분말, 시럽 등과 같은 경구 투여용 제형; 및 정맥내, 근육내 또는 피하 주사용 주사 용액 또는 현탁액, 흡입제, 안약, 비강 점적, 좌제와 같은 비경구 투여용 제형; 또는 연고와 같은 경피 제형으로 제형화될 수 있다.When using the compounds of formula (I) of the invention in therapy, the compounds may be formulated in common formulations for oral and parenteral administration. Pharmaceutical compositions containing a compound of formula (I) of the invention may be in forms for oral and parenteral administration. In particular, the compounds may be formulated for oral administration such as tablets, capsules, granules, powders, syrups and the like; And formulations for parenteral administration such as intravenous, intramuscular or subcutaneous injection solutions or suspensions, inhalants, eye drops, nasal drops, suppositories; Or in transdermal formulations such as ointments.

제형을 제조하는데 있어서, 당 분야의 일반적인 숙련자들에게 공지되어 있는 담체, 부형제, 용매 및 염기를 사용할 수도 있다. 정제의 경우, 보조 성분과 함께 활성 성분을 압착하거나 또는 배합함으로써 제조한다. 유용한 보조 성분의 예로는 결합제(예: 옥수수 전분), 충전제(예: 락토즈, 미정질 셀룰로즈), 붕해제(예: 전분나트륨 글리콜레이트) 또는 윤활제(예: 마그네슘 스테아레이트)와 같은 약학적으로 허용가능한 부형제를 들 수 있다. 정제는 적절하게 피복될 수도 있다. 시럽, 용액 또는 현탁액과 같은 액체 제형의 경우, 현탁제(예: 메틸 셀룰로즈), 유화제(예: 레시틴), 방부제 등을 포함할 수도 있다. 주사용 제형의 경우, 이는 현탁액-안정화제 또는 분산제 등을 함유할 수도 있는 용액 또는 현탁액, 또는 오일상 또는 수성 유화액의 형태일 수 있다. 흡입제의 경우, 흡입기에 적절한 액체 제형으로 제형화된다. 안약의 경우,용액 또는 현탁액으로 제형화된다. 특히, 코의 폐색증의 치료를 위한 비강 약제의 경우, 종래의 제형화 방법으로 제조된 용액 또는 현탁액으로서 또는 분말제(예: 하이드록시프로필 셀룰로즈, 카보폴)를 사용하여 제형화한 분말로서 사용할 수 있으며, 비강내로 투여된다. 선택적으로, 낮은 비점의 용매와 함께특별한 용기에 충전시킨 후 에어로졸로서 사용할 수 있다.In preparing the formulations, carriers, excipients, solvents and bases known to those skilled in the art may be used. In the case of tablets, it is prepared by pressing or blending the active ingredient with the auxiliary ingredient. Examples of useful auxiliary ingredients include pharmaceuticals such as binders (e.g. corn starch), fillers (e.g. lactose, microcrystalline cellulose), disintegrants (e.g. sodium starch glycolate) or lubricants (e.g. magnesium stearate). Acceptable excipients. Tablets may be appropriately coated. In the case of liquid formulations such as syrups, solutions or suspensions, suspending agents (eg methyl cellulose), emulsifiers (eg lecithin), preservatives and the like may be included. In the case of injectable formulations, it may be in the form of a solution or suspension, which may contain suspension-stabilizers or dispersants, or the like, or an oily or aqueous emulsion. In the case of inhalants, it is formulated in a liquid formulation suitable for the inhaler. In the case of eye drops, they are formulated in solutions or suspensions. In particular, nasal agents for the treatment of nasal obstruction can be used as solutions or suspensions prepared by conventional formulation methods or as powders formulated using powders (e.g., hydroxypropyl cellulose, Carbopol). It is administered intranasally. Alternatively, it can be used as an aerosol after filling into a special container with a low boiling solvent.

화학식 I의 화합물의 적절한 투여량은 투여 경로, 환자의 연령, 체중, 성별 또는 상태, 및 함께 사용되는 약제의 종류(있는 경우)에 따라 변하기 때문에 결국 의사의 처방에 따라야 하지만, 경구 투여의 경우, 1일 사용량은 일반적으로 체중 1 kg 당 약 0.01 내지 100 mg, 바람직하게는 약 0.01 내지 10 mg, 보다 바람직하게는 약 0.1 내지 10 mg일 수 있다. 비경구 투여의 경우, 1일 투여량은 일반적으로 체중 1 kg당 약 0.001 내지 100 mg, 바람직하게는 약 0.001 내지 1 mg, 보다 바람직하게는 약 0.01 내지 1 mg일 수 있다. 1일 투여량은 1 내지 4 회로 나누어 투여될 수 있다.Appropriate dosages of the compounds of formula (I) vary according to the route of administration, the age, weight, sex or condition of the patient, and the type of medicament used (if any). The daily dosage may generally be about 0.01 to 100 mg, preferably about 0.01 to 10 mg, more preferably about 0.1 to 10 mg per kg of body weight. For parenteral administration, the daily dosage may generally be about 0.001 to 100 mg, preferably about 0.001 to 1 mg, more preferably about 0.01 to 1 mg per kg of body weight. The daily dose may be administered in one to four divided doses.

하기의 실시예는 본 발명을 추가로 설명하기 위해 제공된 것이지, 본 발명의 범주를 제한하려는 것은 아니다.The following examples are provided to further illustrate the invention, but are not intended to limit the scope of the invention.

실시예 1Example 1

메틸 (Z)-7-[(1S, 2R, 3R, 4R)-3-아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트(II-1) (251 mg, 1.00 mmol)를 메틸렌 클로라이드 (8 ㎖)에 용해시키고, 질소 분위기하에서 트리에틸아민(0.238 ㎖, 2.00 mmol)을 첨가하였다. 빙냉하에서 혼합물에 2-클로로설포닐디벤조푸란(350 mg, 1.31 mmol)을 첨가하고, 이 혼합물을 30분 동안 교반하고 실온까지 승온하였다. 반응 혼합물을 실리카 겔상에서 컬럼 크로마토크래피(n-헥산/에틸 아세테이트 (1:4))에 의해 정제하였고, n-헥산(10 ㎖)으로 재결정화하여 메틸 (Z)-7-[(1S, 2R, 3R, 4R)-3-(2-디벤조푸릴)설포닐아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트(1a-1)(342 mg, 0.710 mmol)를 수득하였다.Methyl (Z) -7-[(1S, 2R, 3R, 4R) -3-aminobicyclo [2.2.1] hept-2-yl] -5-heptenoate (II-1) (251 mg, 1.00 mmol) was dissolved in methylene chloride (8 mL) and triethylamine (0.238 mL, 2.00 mmol) was added under nitrogen atmosphere. 2-chlorosulfonyldibenzofuran (350 mg, 1.31 mmol) was added to the mixture under ice cooling, and the mixture was stirred for 30 minutes and warmed to room temperature. The reaction mixture was purified by column chromatography on silica gel (n-hexane / ethyl acetate (1: 4)) and recrystallized from n-hexane (10 mL) to give methyl (Z) -7-[(1S, 2R, 3R, 4R) -3- (2-dibenzofuryl) sulfonylaminobicyclo [2.2.1] hept-2-yl] -5-heptenoate (1a-1) (342 mg, 0.710 mmol) Obtained.

수율: 71%, 융점(mp): 115-116℃.Yield: 71%, Melting Point (mp): 115-116 ° C.

원소분석(C27H31NO5S)Elemental Analysis (C 27 H 31 NO 5 S)

계산치 (%) : C, 67.34; H, 6.49; N, 2.91; S,Calculated (%): C, 67.34; H, 6. 49; N, 2.91; S,

측정치 (%) : C, 67.16; H, 6.47; N, 2.99, S,Found (%): C, 67.16; H, 6. 47; N, 2.99, S,

메틸 (Z)-7-[(1S,2R,3R,4R)-3-(2-디벤조푸릴)-설포닐아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트 (1a-1)(234 mg, 0.50 mmol)를 메탄올 (6 ㎖)/테트라하이드로푸란(4 ㎖)에 용해시켰다. 빙냉하에서 용액에 1 N 칼륨 하이드록사이드 (1.50 ㎖, 1.50 mmol)를 첨가하였다. 반응 혼합물을 실온까지 승온한 다음, 16시간 동안 반응시키고 농축시켜 용매를 제거하였다. 잔류물에 에틸 아세테이트(50 ㎖) 및 물 (10 ㎖)을 첨가하고, 그 다음 1N HCl (2.00 ㎖, 2.00 mmol)을 첨가한 후, 유기층을 분리하였다. 유기층을 포화 염수로 세척하고, 무수 나트륨 설페이트로 건조시킨 다음 농축시켰다. 잔류물을 실리카 겔상에서 컬럼 크로마토크래피(0.2% 아세트산을 함유하는 n-헥산/에틸 아세테이트 (1:1))에 의해 정제하여 (Z)-7-[(1S, 2R, 3R, 4R)-3-(2-디벤조푸릴)-설포닐아미노비사이클로[2.2.1]헵트-2-일]-5-헨텐산(1a-2) (203 mg, 0.434 mmol)을 수득하였다.Methyl (Z) -7-[(1S, 2R, 3R, 4R) -3- (2-dibenzofuryl) -sulfonylaminobicyclo [2.2.1] hept-2-yl] -5-heptenoate (1a-1) (234 mg, 0.50 mmol) was dissolved in methanol (6 mL) / tetrahydrofuran (4 mL). 1 N potassium hydroxide (1.50 mL, 1.50 mmol) was added to the solution under ice cooling. The reaction mixture was raised to room temperature, then reacted for 16 hours and concentrated to remove the solvent. Ethyl acetate (50 mL) and water (10 mL) were added to the residue, followed by 1N HCl (2.00 mL, 2.00 mmol), and then the organic layer was separated. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and then concentrated. The residue was purified by column chromatography on silica gel (n-hexane / ethyl acetate with 0.2% acetic acid (1: 1)) to give (Z) -7-[(1S, 2R, 3R, 4R)- 3- (2-Dibenzofuryl) -sulfonylaminobicyclo [2.2.1] hept-2-yl] -5-hentenic acid (1a-2) (203 mg, 0.434 mmol) was obtained.

수율: 87%, 오일상.Yield 87%, oily phase.

(Z)-7-[(1S,2R,3R,4R)-3-(2-디벤조푸릴)설포닐아미노비사이클로[2.2.1]헵트-2-일]-5-헨텐산(1a-2) (453 mg, 0.97 mmol)을 메탄올 (5 ㎖)에 용해시켰다. 1N 나트륨 메톡사이드/메탄올 (1.034 N, 0.937 ㎖, 0.97 mmol)을 첨가한 후, 혼합물을실온까지 가온하고 1시간 동안 반응시켰다. 증류에 의해 용매를 제거하여, 나트륨염(1a-3) (457 mg, 0.933 mmol)을 수득하였다.(Z) -7-[(1S, 2R, 3R, 4R) -3- (2-dibenzofuryl) sulfonylaminobicyclo [2.2.1] hept-2-yl] -5-hentenic acid (1a- 2) (453 mg, 0.97 mmol) was dissolved in methanol (5 mL). After addition of 1N sodium methoxide / methanol (1.034 N, 0.937 mL, 0.97 mmol), the mixture was allowed to warm to room temperature and reacted for 1 hour. The solvent was removed by distillation to give sodium salt (1a-3) (457 mg, 0.933 mmol).

수율: 96%, 미정질 분말.Yield: 96%, microcrystalline powder.

원소 분석 (C26H28NO5SNa 0.6H2O)Elemental Analysis (C 26 H 28 NO 5 SNa 0.6H 2 O)

계산치 (%) : C, 62.41; H, 5.88; N, 2.80; S, 6.41; Na, 4.59Calculated (%): C, 62.41; H, 5.88; N, 2.80; S, 6.41; Na, 4.59

측정치 (%) : C, 62.45; H, 5.92; N, 2.99; S, 6.49; Na, 4.46Measured (%): C, 62.45; H, 5.92; N, 2.99; S, 6.49; Na, 4.46

실시예 2Example 2

일본 특허 공고 공보 제 93-79060 호의 참조예 4에서 기술한 방법으로 제조한 메틸 (Z)-7-[(1S,2R,3R,4R)-3-아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트 트리플루오로아세테이트(II-2) (232 mg, 0.636 mmol)를 메틸렌 클로라이드(5 ㎖)에 용해시켰다. 빙냉하에서 이 용액에 트리에틸아민(0.279 ㎖, 2.00 mmol) 및 4-비페닐카보닐 클로라이드를 첨가하고, 동일 온도에서 7시간동안 교반하였다. 반응 혼합물을 실리카 겔상에서 컬럼 크로마토크래피(에틸 아세테이트/n-헥산 (1:4))에 의해 정제하여 (Z)-7-[(1S,2R,3R,4R)-3-(4-비페닐)카보닐아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트(1k-11) (221 mg, 0.512 mmol)를 수득하였다. 화합물(1K-11) (190 mg, 0.440 mmol)을 메탄올(6 ㎖)에 용해시켰다. 빙냉하에서 용액에 1N KOH(1.10 ㎖, 1.10 mmol)를 첨가하고 실온에서 15시간동안 교반하였다.Methyl (Z) -7-[(1S, 2R, 3R, 4R) -3-aminobicyclo [2.2.1] hept-2 prepared by the method described in Reference Example 4 of Japanese Patent Publication No. 93-79060 -Yl] -5-heptenoate trifluoroacetate (II-2) (232 mg, 0.636 mmol) was dissolved in methylene chloride (5 mL). Triethylamine (0.279 mL, 2.00 mmol) and 4-biphenylcarbonyl chloride were added to this solution under ice-cooling, and stirred for 7 hours at the same temperature. The reaction mixture was purified by column chromatography on silica gel (ethyl acetate / n-hexane (1: 4)) to give (Z) -7-[(1S, 2R, 3R, 4R) -3- (4-ratio Phenyl) carbonylaminobicyclo [2.2.1] hept-2-yl] -5-heptenoate (1k-11) (221 mg, 0.512 mmol) was obtained. Compound (1K-11) (190 mg, 0.440 mmol) was dissolved in methanol (6 mL). 1N KOH (1.10 mL, 1.10 mmol) was added to the solution under ice-cooling and stirred at room temperature for 15 hours.

진공하에서 반응 혼합물을 농축시켰다. 물 (20 ㎖) 및 1N HCl(2 ㎖)을 첨가한 후, 잔류물을 에틸 아세테이트로 추출하였다. 유기층을 포화 염수로 세척하고, 무수 나트륨 설페이트로 건조시킨 후, 농축시켰다. 잔류물을 실리카 겔상에서 컬럼 크로마토크래피(0.3% 아세트산을 함유하는 에틸 아세테이트/헥산 (1:1))에 의해 정제하여 (Z)-7-[(1S,2R,3R,4R)-3-(4-비페닐)카보닐아미노비사이클로[2.2.1]헵트-2-일]-5-헨텐산(1k-12) (172 mg, 0.412 mmol)을 수득하였다.The reaction mixture was concentrated in vacuo. After addition of water (20 mL) and 1N HCl (2 mL), the residue was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and then concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate / hexanes with 0.3% acetic acid (1: 1)) to give (Z) -7-[(1S, 2R, 3R, 4R) -3- (4-biphenyl) carbonylaminobicyclo [2.2.1] hept-2-yl] -5-hentenic acid (1k-12) (172 mg, 0.412 mmol) was obtained.

수율; 94%.yield; 94%.

또한, 하기의 화합물을 하기의 방법으로 제조할 수 있다.In addition, the following compounds can be produced by the following method.

실시예 3Example 3

질소 분위기하의 실온에서 4-카복시부틸트리페닐포스포늄 브로마이드(14.8 g, 33.3 mmol) 및 테트라하이드로푸란(80 ㎖)의 현탁액에 칼륨 3급-부티레이트(7.55g, 67.3 mmol)를 첨가하였다. 실온에서 1시간동안 교반한 후, 혼합물을 -20℃로 냉각시키고, 테트라하이드로푸란 (20㎖)내 N-(1S,2S,3S,4R)-3-포르밀메틸비사이클로[2.2.1]헵트-2-일]벤젠설폰아미드(III-1) (일본 특허 공개 공보 제 90-256650 호, 참조예 2)(3.25 g, 11.1 mmol)의 용액을 천천히 첨가하였다. -20℃에서 약 1시간 동안 교반한 후, 냉욕을 제거하고, 1시간 동안 추가로 혼합물을 교반하였다. 반응 용액에 2N HCl를 첨가하고, 혼합물을 에틸 아세테이트로 추출하고, 물 및 염수로 세척한 후 농축시켰다. 톨루엔 및 1N 수산화나트륨을 생성된 조질의 생성물에 첨가한 후 수성층을 분리하였다. 유기층을 물로 다시 세척하고, 세척액을 앞서 얻은 수성층과 합쳤다. 2N HCl를 첨가한 후, 수용액을 에틸 아세테이트로 추출하였다. 추출물을 물 및 염수로 세척하고, 나트륨 설페이트로 건조시킨 후 농축시켰다. 잔류물을 실리카 겔상에서 컬럼 크로마토크래피에 의해 정제하여 칼슘 (Z)-7-[(1R,2S,3S,4S)-3-페닐설포닐아미노비사이클로[2.2.1]헵트-2-일]-5-헵테노에이트(1d-1) (3.29 g)를 수득하였다.To a suspension of 4-carboxybutyltriphenylphosphonium bromide (14.8 g, 33.3 mmol) and tetrahydrofuran (80 mL) at room temperature under nitrogen atmosphere was added potassium tert-butyrate (7.55 g, 67.3 mmol). After stirring at room temperature for 1 hour, the mixture was cooled to -20 ° C and N- (1S, 2S, 3S, 4R) -3-formylmethylbicyclo [2.2.1] in tetrahydrofuran (20 mL). A solution of hept-2-yl] benzenesulfonamide (III-1) (JP-A-90-256650, Reference Example 2) (3.25 g, 11.1 mmol) was slowly added. After stirring at −20 ° C. for about 1 hour, the cold bath is removed and the mixture is further stirred for 1 hour. 2N HCl was added to the reaction solution, the mixture was extracted with ethyl acetate, washed with water and brine and then concentrated. Toluene and 1N sodium hydroxide were added to the resulting crude product and the aqueous layer was separated. The organic layer was washed again with water and the wash was combined with the aqueous layer obtained earlier. After addition of 2N HCl, the aqueous solution was extracted with ethyl acetate. The extract was washed with water and brine, dried over sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel to give calcium (Z) -7-[(1R, 2S, 3S, 4S) -3-phenylsulfonylaminobicyclo [2.2.1] hept-2-yl ] -5-heptenoate (1d-1) (3.29 g) was obtained.

수율: 79%, mp: 62℃.Yield: 79%, mp: 62 ° C.

원소 분석 (C20H27NO4S)Elemental Analysis (C 20 H 27 NO 4 S)

계산치 (%) ; C, 63.63; H, 7.21; N, 3.71; S, 8.49Calculated value (%); C, 63.63; H, 7. 21; N, 3.71; S, 8.49

측정치 (%) : C, 63.56; H, 7.21; N, 3.83; S, 8.43Found (%): C, 63.56; H, 7. 21; N, 3.83; S, 8.43

상기 실시예에서 기술한 방법에 따라 제조된 화합물을 하기 표에 제시하였다.Compounds prepared according to the methods described in the above examples are shown in the table below.

표 1aTable 1a

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1a (계속)Table 1a (continued)

표 1bTable 1b

표 1b (계속)Table 1b (continued)

표 1cTable 1c

표 1dTable 1d

표 1d (계속)Table 1d (continued)

표 1eTable 1e

표 1fTable 1f

표 1gTable 1g

표 1hTable 1h

표 1iTable 1i

표 1jTable 1j

표 1j (계속)Table 1j (continued)

표 1j (계속)Table 1j (continued)

표 1kTable 1k

표 1k (계속)Table 1k (continued)

표 1aTable 1a

표 1m (계속)Table 1m (continued)

표 1m (계속)Table 1m (continued)

표 2aTable 2a

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2a (계속)Table 2a (continued)

표 2bTable 2b

표 2cTable 2c

표 2dTable 2d

표 2eTable 2e

표 2fTable 2f

표 2gTable 2g

표 2hTable 2h

표 2iTable 2i

표 2jTable 2j

표 2kTable 2k

표 3aTable 3a

표 3a (계속)Table 3a (continued)

표 3bTable 3b

표 3cTable 3c

표 3dTable 3d

표 3d (계속)Table 3d (continued)

표 3eTable 3e

상기 화합물들의 물리화학적 특성은 하기와 같다. 화합물의 번호는 상기 표들의 번호에 상응한다.Physical and chemical properties of the compounds are as follows. The number of compounds corresponds to the number in the tables above.

상기 실시예에서 제조한 화합물을 하기의 실험 실시예에서 제시하는 방법에 따라 생체내 활성 및 시험관내 활성을 시험하였다.The compounds prepared in the above examples were tested for in vivo activity and in vitro activity according to the method shown in the experimental examples below.

실험 1PGD2수용체에의 결합 Experiment 1 Binding to PGD 2 Receptor

물질 및 방법Substances and Methods

(1) 인간 혈소판 막 분획의 제조(1) Preparation of human platelet membrane fraction

3.8% 나트륨 시트레이트를 함유하는 플라스틱 주사기를 사용하여 건강한 지원자(성인 남자 및 여자)의 정맥으로부터 혈액 샘플을 수득하고, 플라스틱 시험관에 담고, 뒤집어서 부드럽게 혼합하였다. 그 다음, 샘플을 실온에서 1800 rpm으로 10분동안 원심분리시키고, PRP(혈소판이 많은 플라즈마; platelet rich plasma)를 함유하는 상청액을 수집하였다. PRP를 실온에서 2300 rpm으로 22분동안 재원심분리시켜 혈소판을 수득하였다. 혈소판을 균질화기(울트라-투락스(Ultra-Turrax))를 사용하여 균질화시키고, 4℃에서 20,000 rpm으로 10분간 3회 원심분리시켜 혈소판 막 분획을 수득하였다. 단백질 측정을 한 후, 막 분획을 2 mg/㎖가 되도록 조정하여 사용할 때까지 -80℃의 냉장고에서 보존하였다.Blood samples were obtained from the veins of healthy volunteers (male and female) using plastic syringes containing 3.8% sodium citrate, placed in plastic test tubes, upside down and gently mixed. The samples were then centrifuged at 1800 rpm for 10 minutes at room temperature and the supernatants containing PRP (platelet rich plasma) collected. PRP was recentrifuged at 2300 rpm for 22 minutes at room temperature to give platelets. Platelets were homogenized using a homogenizer (Ultra-Turrax) and centrifuged three times for 10 minutes at 20,000 rpm at 4 ° C. to obtain platelet membrane fractions. After measuring the protein, the membrane fractions were adjusted to 2 mg / ml and stored in a refrigerator at -80 ° C until use.

(2) PGD2수용체에의 결합(2) binding to PGD 2 receptor

결합-반응 용액(50 mM, 트리스(Tris)/HCl, pH 7.4, 5 mM MgCl2)(0.2㎖)에 인간 혈소판 막 분획(0.1 mg) 및 5 nM [3H]PGD2(115 Ci/mmol)를 첨가하고, 4℃에서 90분간 반응시킨다. 반응이 완료된 후, 반응 혼합물을 유리 섬유 여과지를 통해 여과하고, 냉각된 식염수로 수 회 세척하고, 여과지에 잔류하는 방사능을 측정하였다. 총 결합량에서 비-특이성 결합량(10 μM PGD2의 존재하의 결합랑)을 빼서 특이성 결합량을 계산하였다. 각 화합물의 결합-억제 활성은 결합을 50% 억제하는데 필요한 농도(IC50)로 표현되고, 이것은 화합물의 존재하의 결합율(%)을 좌표에 나타내어 치환 곡선을 그려서 결정하며, 이때 시험 화합물의 부재하의 결합율은 100%이다. 결과를 하기 표에 제시하였다.Human platelet membrane fraction (0.1 mg) and 5 nM [ 3 H] PGD 2 (115 Ci / mmol) in a binding-reaction solution (50 mM, Tris / HCl, pH 7.4, 5 mM MgCl 2 ) (0.2 ml) ) Is added and reacted at 4 ° C for 90 minutes. After the reaction was completed, the reaction mixture was filtered through glass fiber filter paper, washed several times with cooled saline and the radioactivity remaining on the filter paper was measured. Specific binding amount was calculated by subtracting the non-specific binding amount (coating in the presence of 10 μM PGD 2 ) from the total binding amount. The binding-inhibiting activity of each compound is expressed as the concentration required to inhibit 50% of the binding (IC 50 ), which is determined by plotting the substitution curve by plotting the percentage of binding in the presence of the compound, wherein the absence of the test compound Bonding rate is 100%. The results are shown in the table below.

실험 2인간 혈소판을 사용한 PGD2수용체에 대한 길항 활성 평가 Experiment 2 Evaluation of Antagonistic Activity of PGD 2 Receptor Using Human Platelets

주사기 용적의 1/9를 시트르산/덱스트로즈 용액으로 미리 채운 주사기를 사용하여 건강한 지원자로부터 말초 혈액을 수득하였다. 주사기를 10분 동안 180g에서 원심 분리시켜 상청액(PRP; 혈소판이 많은 플라즈마)을 수득하였다. 수득한 PRP를 3회에 걸쳐 세척용 완충액으로 세척하고, 혈소판의 갯수를 마이크로 세포 계수기(micro cell counter)를 사용하여 계수하였다. 혈소판의 최종 농도가 5×108/㎖이도록 조정한 현탁액을 37℃로 가온하고, 그 다음 3-이소부틸-1-메틸크산틴(0.5 mM)으로 5분동안 예비처리하였다. 현탁액에 다양한 농도로 희석시킨 시험 화합물을 첨가하였다. 10분 후에, 0.1 내지 2.0 μM의 PGD2를 첨가함으로써 반응을 유도하였고, 15분 후에 HCl를 첨가함으로써 반응을 종결시켰다. 초음파 균질화기로 혈소판을 파괴하였다. 원심분리후에, 상청액중의 cAMP를 방사 분석하여 결정하였다. 약제의 PGD2수용체 길항작용을 하기와 같이 평가하였다. PGD2를 첨가함으로써 증가하는cAMP에 대한 억제율을 각각의 농도에 대하여 측정한 다음, 50% 억제하는데 필요한 약제의 농도(IC50)를 계산하였다. 결과를 하기 표에 제시하였다.Peripheral blood was obtained from healthy volunteers using a syringe prefilled with 1/9 of the syringe volume with citric acid / dextrose solution. The syringe was centrifuged at 180 g for 10 minutes to obtain supernatant (PRP; platelet-rich plasma). The obtained PRP was washed three times with washing buffer and the number of platelets was counted using a micro cell counter. The suspension, adjusted to a final concentration of platelets of 5 × 10 8 / ml, was warmed to 37 ° C. and then pretreated with 3-isobutyl-1-methylxanthine (0.5 mM) for 5 minutes. To the suspension was added test compounds diluted to various concentrations. After 10 minutes, the reaction was induced by adding 0.1-2.0 μM PGD 2 , and after 15 minutes the reaction was terminated by addition of HCl. The platelet was destroyed by an ultrasonic homogenizer. After centrifugation, cAMP in the supernatant was determined by radioanalysis. PGD 2 receptor antagonism of the drug was evaluated as follows. Inhibition of increasing cAMP by adding PGD 2 was measured for each concentration, and then the concentration of drug required to inhibit 50% (IC 50 ) was calculated. The results are shown in the table below.

실험 3코의 폐색증 모델을 사용한 실험 Experiment 3 Experiment Using Nose Occlusion Model

기니아 피그를 사용하여, 비강 저항성을 측정하고 코 폐색에 대한 저항성을 측정하는 방법을 하기와 같이 기술하였다.Using guinea pigs, a method of measuring nasal resistance and resistance to nasal obstruction is described as follows.

1% 오발부민(OVA) 용액을 초음파 분무기로 처리하여 에어로졸을 수득하였다. 하틀리(Hartley) 수컷 기니아 피그를 1주일 간격을 두고 10 분동안 두번 에어로졸을 흡입시켜 증감시켰다. 증감시키고 7일 후, 기니아 피그를 항원에 노출시켜 반응을 개시시켰다. 그 다음, 펜토바비칼(30 mg/kg, 복강내)로 마취시킨 상태에서 기관을 절개하여, 폐쪽 및 비강쪽에서 캐뉼라(cannula)를 기관으로 삽입하였다. 폐쪽에 삽입된 캐뉼라를, 4㎖의 공기를 60 회/분으로 제공하는 인공 호흡기와 연결시켰다. 가라민(2 mg/kg, 정맥내)으로 기니아 피그의 자발적인 호흡을 저지시킨 후, 4 ㎖ 공기/회의 유속, 70회/분의 빈도로 인공 호흡기가 달린 관의 주둥이에 공기를 공급하였고, 통기에 요구되는 대기압을, 분지에 장착한 변환기를 사용하여 측정하였다. 측정치를 비강 저항성의 변수로서 사용하였다. 호흡기와 비강 캐뉼라 사이에 3분동안 3% OVA 용액의 에어로졸을 발생시킴으로써 항원에 노출시켰다. 항원에 노출시키기 전에 시험 약제를 10분동안 정맥내 주사하였다. 0 내지 30분 동안 코의 저항성을 연속적으로 측정하였고, 그 효과를 지표로서 30분 동안 AUC를 사용하여 부형제에 대하여 수득한 효과에 대한 억제율로 표시한다(y 축: 비강의 저항성(cm H2O), x 축: 시간 (0 내지 30 분)). 결과는 하기와 같다.1% Ovalbumin (OVA) solution was treated with an ultrasonic nebulizer to obtain an aerosol. Hartley male guinea pigs were sensitized by inhaling aerosol twice for 10 minutes at weekly intervals. After 7 days of sensitization, the reaction was initiated by exposing the guinea pig to the antigen. The trachea was then dissected under anesthesia with pentobical (30 mg / kg, intraperitoneal), and cannula was inserted into the trachea from the lung and nasal passages. The cannula inserted into the lung was connected to a ventilator providing 4 ml of air at 60 times / min. After spontaneous breathing of guinea pigs with caramine (2 mg / kg, intravenously), air was supplied to the spout of the ventilator tube at 4 ml air / time flow rate, 70 times / minute and ventilated. Atmospheric pressure required at was measured using a transducer mounted on a branch. The measurements were used as variables of nasal resistance. The antigen was exposed by generating an aerosol of 3% OVA solution for 3 minutes between the respiratory and nasal cannula. The test agent was injected intravenously for 10 minutes prior to exposure to the antigen. The resistance of the nose was continuously measured for 0 to 30 minutes, and the effect is expressed as an inhibition rate against the effect obtained for the excipient using AUC for 30 minutes as an index (y axis: resistance of the nasal cavity (cm H 2 O). ), x axis: time (0-30 minutes)). The results are as follows.

제형예 1정제의 제조 Formulation Example 1 Preparation of Tablet

활성 성분 40 mg을 각각 함유하는 정제는 통상의 방법으로 제조하였다. 40mg 정제의 성분은 하기와 같다.Tablets each containing 40 mg of active ingredient were prepared by conventional methods. The components of the 40 mg tablet are as follows.

제형예 2과립의 제조 Formulation Example 2 Preparation of Granules

성분은 다음과 같다:The ingredients are as follows:

Claims (17)

활성 성분으로서 하기 화학식 I의 화합물, 그의 염 또는 이들의 수화물을 포함하는, 전신성 비만 세포증, 전신성 비만 세포 활성화의 장애, 기관 수축, 천식, 알러지성 비염, 알러지성 결막염, 두드러기, 허혈성 재관류로 인한 손상, 염증 및 코의 폐색증으로 구성된 군에서 선택된 질환을 치료하기 위한 약학 조성물:Damages due to systemic mastocytosis, disorders of systemic mast cell activation, organ contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion, including compounds of formula (I), salts or hydrates thereof, as active ingredients Pharmaceutical compositions for treating diseases selected from the group consisting of inflammation, inflammation and nasal obstruction: 화학식 IFormula I 상기 식에서,Where 는 Is 또는이고;or ego; A는 쇄중에 헤테로 원자 또는 페닐렌을 함유하거나 함유하지 않고, 옥소기를 함유하거나 함유하지 않고 불포화 결합을 갖거나 갖지 않는 알킬렌이고;A is alkylene with or without hetero atoms or phenylene in the chain, with or without oxo groups and with or without unsaturated bonds; B는 수소, 알킬, 아르알킬 또는 아실이고;B is hydrogen, alkyl, aralkyl or acyl; R은 COOR1, CH2OR2또는 CON(R3)R4이고;R is COOR 1 , CH 2 OR 2 or CON (R 3 ) R 4 ; R1은 수소 또는 알킬이고;R 1 is hydrogen or alkyl; R2는 수소 또는 알킬이고;R 2 is hydrogen or alkyl; R3및 R4는 각각 독립적으로 수소, 알킬, 하이드록시 또는 알킬설폰일이고;R 3 and R 4 are each independently hydrogen, alkyl, hydroxy or alkylsulfonyl; X1은 단일 결합, 페닐렌, 나프틸렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고;X 1 is a single bond, phenylene, naphthylene, thiophendiyl, indoldiyl or oxazoldiyl; X2는 단일 결합, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-O-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C(Cl)=C(Cl)-, -(CH2)n-, 에틴일렌, -N(R5)-, -N(R51)CO-, -N(R52)SO2-, -N(R53)CON(R54)-, -CON(R55)-, -SO2N(R56)-, -O-, -S-, -SO-, -SO2-, -CO-, 옥사디아졸디일, 티아디아졸디일 또는 테트라졸디일이고;X 2 is a single bond, -N = N-, -N = CH-, -CH = N-, -CH = NN-, -CH = NO-, -C = NNHCSNH-, -C = NNHCONH-, -CH = CH-, -CH (OH)-, -C (Cl) = C (Cl)-,-(CH 2 ) n- , ethynylene, -N (R 5 )-, -N (R 51 ) CO- , -N (R 52 ) SO 2- , -N (R 53 ) CON (R 54 )-, -CON (R 55 )-, -SO 2 N (R 56 )-, -O-, -S-, -SO-, -SO 2- , -CO-, oxadiazolediyl, thiadiazolediyl or tetrazoldiyl; X3은 알킬, 알켄일, 알킨일, 아릴, 아르알킬, 헤테로사이클릭 기, 사이클로알킬, 사이클로알켄일, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸, -CH=NR6또는 -N=C(R7)R8이고;X 3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl, -CH = NR 6 or -N = C (R 7 ) R 8 ; R5, R51, R52, R53, R54, R55및 R56은 각각 수소 또는 알킬이고;R 5 , R 51 , R 52 , R 53 , R 54 , R 55 and R 56 are each hydrogen or alkyl; R6은 수소, 알킬, 하이드록시, 알콕시, 카바모일옥시, 티오카바모일옥시, 우레이도 또는 티오우레이도이고;R 6 is hydrogen, alkyl, hydroxy, alkoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido; R7및 R8은 각각 독립적으로 알킬, 알콕시 또는 아릴이고;R 7 and R 8 are each independently alkyl, alkoxy or aryl; n은 1 또는 2이고;n is 1 or 2; Z는 -SO2- 또는 -CO-이고;Z is -SO 2 -or -CO-; m은 0 또는 1이며;m is 0 or 1; 이때, 사이클릭 치환체는 니트로, 알콕시, 설파모일, 치환되거나 치환되지 않은 아미노, 아실, 아실옥시, 하이드록시, 할로겐, 알킬, 알킨일, 카복시, 알콕시카보닐, 아르알콕시카보닐, 아릴옥시카보닐, 메실옥시, 시아노, 알켄일옥시, 하이드록시알킬, 트리플루오로메틸, 알킬티오, -N=PPh3, 옥소, 티옥소, 하이드록시이미노, 알콕시이미노, 페닐 및 알킬렌디옥시로 구성된 군에서 선택된 1 내지 3개의 치환체를 가질 수도 있다.Wherein the cyclic substituent is nitro, alkoxy, sulfamoyl, substituted or unsubstituted amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl , Mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, -N = PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy It may also have 1 to 3 substituents selected. 제 1 항에 있어서,The method of claim 1, 활성 성분이,Active ingredients, 가이고; end ego; m이 0이고;m is 0; Z가 SO2이고;Z is SO 2 ; X1및 X2가 둘다 단일 결합이고;X 1 and X 2 are both single bonds; X3이 알킬, 페닐, 나프틸, 스틸릴, 퀴놀일 또는 티엔일(이들 치환체중 사이클릭 치환체는 니트로, 알콕시, 치환되거나 치환되지 않은 아미노, 할로겐, 알킬 및 하이드록시알킬로 구성된 군에서 선택된 1 내지 3개의 치환체를 갖거나 갖지 않음)인 화학식 I의 화합물, 그의 염 또는 이들의 수화물인 약학 조성물.X 3 is alkyl, phenyl, naphthyl, stylyl, quinolyl or thienyl, wherein the cyclic substituents are selected from the group consisting of nitro, alkoxy, substituted or unsubstituted amino, halogen, alkyl and hydroxyalkyl To (with or without 3 substituents), a compound of formula (I), a salt thereof or a hydrate thereof. 제 1 항에 있어서,The method of claim 1, 활성 성분이,Active ingredients, 가이고; end ego; m이 1이고;m is 1; X1및 X2가 둘다 단일 결합이고;X 1 and X 2 are both single bonds; X3이 할로겐으로 치환되거나 치환되지 않은 페닐인 화학식 I의 화합물, 그의 염 또는 이들의 수화물인 약학 조성물.A pharmaceutical composition wherein the compound of formula (I), a salt thereof, or a hydrate thereof, wherein X 3 is phenyl unsubstituted or substituted with halogen. 제 1 항에 있어서,The method of claim 1, 활성 성분이,Active ingredients, 가이고; end ego; m이 1이고;m is 1; X1이 페닐렌이고;X 1 is phenylene; X2가 -CH2- 또는 -N=N-이고;X 2 is -CH 2 -or -N = N-; X3이 페닐인 화학식 I의 화합물, 그의 염 또는 이들의 수화물인 약학 조성물.A pharmaceutical composition of formula I, a salt thereof, or a hydrate thereof, wherein X 3 is phenyl. 제 1 항에 있어서,The method of claim 1, 코의 폐색증을 치료하기 위한 약제인 약학 조성물.Pharmaceutical composition, which is a medicament for treating nasal obstruction. 하기 화학식 Ia의 화합물, 그의 염 또는 이들의 수화물:Compounds of formula (Ia), salts thereof or hydrates thereof: 화학식 IaFormula Ia 상기 식에서,Where A는 쇄중에 헤테로 원자 또는 페닐렌을 함유하거나 함유하지 않고, 옥소기를 함유하거나 함유하지 않고, 불포화 결합을 갖거나 갖지 않는 알킬렌이고;A is alkylene with or without hetero atoms or phenylene in the chain, with or without oxo groups, with or without unsaturated bonds; B는 수소, 알킬, 아르알킬 또는 아실이고;B is hydrogen, alkyl, aralkyl or acyl; R은 COOR1, CH2OR2또는 CON(R3)R4이고;R is COOR 1 , CH 2 OR 2 or CON (R 3 ) R 4 ; R1은 수소 또는 알킬이고;R 1 is hydrogen or alkyl; R2는 수소 또는 알킬이고;R 2 is hydrogen or alkyl; R3및 R4는 각각 독립적으로 수소, 알킬, 하이드록시 또는 알킬설폰일이고;R 3 and R 4 are each independently hydrogen, alkyl, hydroxy or alkylsulfonyl; X1은 단일 결합, 페닐렌, 나프틸렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고;X 1 is a single bond, phenylene, naphthylene, thiophendiyl, indoldiyl or oxazoldiyl; X2는 단일 결합, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-O-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C(Cl)=C(Cl)-, -(CH2)n-, 에티닐렌, -N(R5)-, -N(R51)CO-, -N(R52)SO2-, -N(R53)CON(R54)-, -CON(R55)-, -SO2N(R56)-, -O-, -S-, -SO-, -SO2-, -CO-, 옥사디아졸디일, 티아디아졸디일 또는 테트라졸디일이고;X 2 is a single bond, -N = N-, -N = CH-, -CH = N-, -CH = NN-, -CH = NO-, -C = NNHCSNH-, -C = NNHCONH-, -CH = CH-, -CH (OH)-, -C (Cl) = C (Cl)-,-(CH 2 ) n- , ethynylene, -N (R 5 )-, -N (R 51 ) CO- , -N (R 52 ) SO 2- , -N (R 53 ) CON (R 54 )-, -CON (R 55 )-, -SO 2 N (R 56 )-, -O-, -S-, -SO-, -SO 2- , -CO-, oxadiazolediyl, thiadiazolediyl or tetrazoldiyl; X3은 알킬, 알켄일, 알킨일, 아릴, 아르알킬, 헤테로사이클릭 기, 사이클로알킬, 사이클로알켄일, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸, -CH=NR6또는 -N=C(R7)R8이고;X 3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl, -CH = NR 6 or -N = C (R 7 ) R 8 ; R5, R51, R52, R53, R54, R55및 R56은 각각 수소 또는 알킬이고;R 5 , R 51 , R 52 , R 53 , R 54 , R 55 and R 56 are each hydrogen or alkyl; R6은 수소, 알킬, 하이드록시, 알콕시, 카바모일옥시, 티오카바모일옥시, 우레이도 또는 티오우레이도이고;R 6 is hydrogen, alkyl, hydroxy, alkoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido; R7및 R8은 각각 독립적으로 알킬, 알콕시 또는 아릴이고;R 7 and R 8 are each independently alkyl, alkoxy or aryl; n은 1 또는 2이고,n is 1 or 2, 이때, 사이클릭 치환체는 니트로, 알콕시, 설파모일, 치환되거나 치환되지 않은 아미노, 아실, 아실옥시, 하이드록시, 할로겐, 알킬, 알킨일, 카복시, 알콕시카보닐, 아르알콕시카보닐, 아릴옥시카보닐, 메실옥시, 시아노, 알켄일옥시, 하이드록시알킬, 트리플루오로메틸, 알킬티오, -N=PPh3, 옥소, 티옥소, 하이드록시이미노, 알콕시이미노, 페닐 및 알킬렌디옥시로 구성된 군에서 선택된 1 내지 3개의 치환체를 가질 수도 있으나,Wherein the cyclic substituent is nitro, alkoxy, sulfamoyl, substituted or unsubstituted amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl , Mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, -N = PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy May have 1 to 3 substituents selected, 단,only, (1) X1및 X2가 단일 결합이고, X3이 치환되거나 치환되지 않은 페닐 또는 나프틸인 경우, (2) A가 5-헵텐일렌이고, R이 COOR1(이때, R1은 수소 또는 메틸임)이고, X1이 1,4-페닐렌이고, X2가 단일 결합이고, X3이 치환되지 않은 페닐인 경우, (3) X1및 X2가 단일 결합이고, X3이 메틸, n-헥실, 2-사이클로헥실에틸, 벤질, 펜에틸 또는 치환되거나 치환되지 않은 알켄일인 경우 및 (4) X1및 X2가 단일 결합이고, X3이 피리딜인 경우를 제외한다.(1) when X 1 and X 2 are a single bond and X 3 is substituted or unsubstituted phenyl or naphthyl, (2) A is 5-heptenylene and R is COOR 1 wherein R 1 is hydrogen Or methyl), X 1 is 1,4-phenylene, X 2 is a single bond, and X 3 is unsubstituted phenyl, (3) X 1 and X 2 are single bonds, and X 3 is Except when methyl, n-hexyl, 2-cyclohexylethyl, benzyl, phenethyl or substituted or unsubstituted alkenyl and (4) X 1 and X 2 are single bonds and X 3 is pyridyl. 제 6 항에 있어서,The method of claim 6, X1및 X2가 단일 결합이고; X3이 이속사졸일, 티아디아졸일, 이소티아졸일, 모폴릴, 인돌일, 벤조푸릴, 디벤조푸릴, 디벤조디옥신일, 벤조티엔일, 디벤조티엔일, 카바졸일, 크산텐일, 페난트리딘일, 디벤즈옥세핀일, 디벤조티에핀일, 시놀일, 크로멘일, 벤즈이미다졸일, 디하이드로벤조티에핀일 또는 디벤조피란일인 화합물, 그의 염 또는 이들의 수화물.X 1 and X 2 are single bonds; X 3 is isoxazolyl, thiadiazolyl, isothiazolyl, morpholyl, indolyl, benzofuryl, dibenzofuryl, dibenzodioxinyl, benzothienyl, dibenzothienyl, carbazolyl, xanthenyl, phenan Compounds, salts or hydrates thereof, which are tridinyl, dibenzoxepinyl, dibenzothiepinyl, synolyl, chromanyl, benzimidazolyl, dihydrobenzothiefinyl or dibenzopyranyl. 제 6 항에 있어서,The method of claim 6, X1이 페닐렌이고; X2가 단일 결합이고; X3이 알켄일, 알킨일, -CH=NR6또는 -N=C(R7)R8인 화합물, 그의 염 또는 이들의 수화물.X 1 is phenylene; X 2 is a single bond; A compound wherein X 3 is alkenyl, alkynyl, —CH═NR 6 or —N═C (R 7 ) R 8 , salts thereof or hydrates thereof. 제 6 항에 있어서,The method of claim 6, R이 COOR1이고; X1이 페닐렌, 티오펜디일 또는 인돌디일이고; X2가 단일 결합, -N=N-, -CH=CH-, -CONH-, -NHCO-, 에틴일렌, -N=CH-, -(CH2)n-, -N(R5)-, -O-, -S-, -SO2-, -CO-, 옥사디아졸디일 또는 테트라졸디일이고; X3이 페닐, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸, 티엔일, 사이클로헥실, 1-사이클로헥센일, n-헥실, 인돌릴 또는 벤즈옥사졸일인 화합물, 그의 염 또는 이들의 수화물.R is COOR 1 ; X 1 is phenylene, thiophendiyl or indoldiyl; X 2 is a single bond, -N = N-, -CH = CH-, -CONH-, -NHCO-, ethynylene, -N = CH-,-(CH 2 ) n- , -N (R 5 )- , -O-, -S-, -SO 2- , -CO-, oxadiazolediyl or tetrazoldiyl; X 3 is phenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl, thienyl, cyclohexyl, 1-cyclohexenyl, n-hexyl, indolyl or benzoxazolyl, salts or hydrates thereof. 하기 화학식 Ib의 화합물, 그의 염 또는 이들의 수화물.A compound of formula (Ib), a salt thereof, or a hydrate thereof. 화학식 IbFormula Ib 상기 식에서,Where 는또는이고; Is or ego; A는 쇄중에 헤테로 원자 또는 페닐렌을 함유하거나 함유하지 않고, 옥소기를 함유하거나 함유하지 않고, 불포화 결합을 갖거나 갖지 않는 알킬렌이고;A is alkylene with or without hetero atoms or phenylene in the chain, with or without oxo groups, with or without unsaturated bonds; B는 수소, 알킬, 아르알킬 또는 아실이고;B is hydrogen, alkyl, aralkyl or acyl; R은 COOR1, CH2OR2또는 CON(R3)R4이고;R is COOR 1 , CH 2 OR 2 or CON (R 3 ) R 4 ; R1은 수소 또는 알킬이고;R 1 is hydrogen or alkyl; R2는 수소 또는 알킬이고;R 2 is hydrogen or alkyl; R3및 R4는 각각 독립적으로 수소, 알킬, 하이드록시 또는 알킬설폰일이고;R 3 and R 4 are each independently hydrogen, alkyl, hydroxy or alkylsulfonyl; X1은 단일 결합, 페닐렌, 나프틸렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고;X 1 is a single bond, phenylene, naphthylene, thiophendiyl, indoldiyl or oxazoldiyl; X2는 단일 결합, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-O-, -C=NNHCSNH-,-C=NNHCONH-, -CH=CH-, -CH(OH)-, -C(Cl)=C(Cl)-, -(CH2)n-, 에티닐렌, -N(R5)-, -N(R51)CO-, -N(R52)SO2-, -N(R53)CON(R54)-, -CON(R55)-, -SO2N(R56)-, -O-, -S-, -SO-, -SO2-, -CO-, 옥사디아졸디일, 티아디아졸디일 또는 테트라졸디일이고;X 2 is a single bond, -N = N-, -N = CH-, -CH = N-, -CH = NN-, -CH = NO-, -C = NNHCSNH-,-C = NNHCONH-, -CH = CH-, -CH (OH)-, -C (Cl) = C (Cl)-,-(CH 2 ) n- , ethynylene, -N (R 5 )-, -N (R 51 ) CO- , -N (R 52 ) SO 2- , -N (R 53 ) CON (R 54 )-, -CON (R 55 )-, -SO 2 N (R 56 )-, -O-, -S-, -SO-, -SO 2- , -CO-, oxadiazolediyl, thiadiazolediyl or tetrazoldiyl; X3은 알킬, 알켄일, 알킨일, 아릴, 아르알킬, 헤테로사이클릭 기, 사이클로알킬, 사이클로알켄일, 티아졸린일리덴메틸, 티아졸리딘일리덴메틸, -CH=NR6또는 -N=C(R7)R8이고;X 3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidineylidenemethyl, -CH = NR 6 or -N = C (R 7 ) R 8 ; R5, R51, R52, R53, R54, R55및 R56은 각각 수소 또는 알킬이고;R 5 , R 51 , R 52 , R 53 , R 54 , R 55 and R 56 are each hydrogen or alkyl; R6은 수소, 알킬, 하이드록시, 알콕시, 카바모일옥시, 티오카바모일옥시, 우레이도 또는 티오우레이도이고;R 6 is hydrogen, alkyl, hydroxy, alkoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido; R7및 R8은 각각 독립적으로 알킬, 알콕시 또는 아릴이고;R 7 and R 8 are each independently alkyl, alkoxy or aryl; n은 1 또는 2이고;n is 1 or 2; 이때, 사이클릭 치환체는 니트로, 알콕시, 설파모일, 치환되거나 치환되지 않은 아미노, 아실, 아실옥시, 하이드록시, 할로겐, 알킬, 알킨일, 카복시, 알콕시카보닐, 아르알콕시카보닐, 아릴옥시카보닐, 메실옥시, 시아노, 알켄일옥시, 하이드록시알킬, 트리플루오로메틸, 알킬티오, -N=PPh3, 옥소, 티옥소, 하이드록시이미노, 알콕시이미노, 페닐 및 알킬렌디옥시로 구성된 군에서 선택된 1 내지 3개의 치환체를 가질 수도 있고,Wherein the cyclic substituent is nitro, alkoxy, sulfamoyl, substituted or unsubstituted amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl , Mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, -N = PPh 3 , oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy May have 1 to 3 substituents selected, 단, X1및 X2가 단일 결합이고, X3이 치환되지 않은 페닐인 경우와 X1이 단일 결합이고, X2가 -O-이고, X3이 벤질인 경우를 제외한다.Provided that X 1 and X 2 are a single bond, X 3 is unsubstituted phenyl, and X 1 is a single bond, X 2 is —O— and X 3 is benzyl. 제 10 항에 있어서,The method of claim 10, 가인 화합물, 그의 염 또는 이들의 수화물. end Phosphorus compounds, salts thereof or hydrates thereof. 제 11 항에 있어서,The method of claim 11, R이 COOR1인 화합물, 그의 염 또는 이들의 수화물.A compound wherein R is COOR 1 , a salt thereof, or a hydrate thereof. 제 11 항에 있어서,The method of claim 11, X1이 페닐렌 또는 티오펜디일이고, X2가 단일 결합, -N=N-, -CH=CH-, 에틴일렌, -O-, -S-, -CO-, -CON(R55)- 또는 -N(R51)CO-이고, X3이 페닐 또는 티엔일인 화합물, 그의 염 또는 이들의 수화물.X 1 is phenylene or thiophendiyl, X 2 is a single bond, -N = N-, -CH = CH-, ethynylene, -O-, -S-, -CO-, -CON (R 55 ) Or -N (R 51 ) CO- and X 3 is phenyl or thienyl, salts thereof or hydrates thereof. 제 10 항에 있어서,The method of claim 10, 가인 화합물, 그의 염 또는 이들의 수화물. end Phosphorus compounds, salts thereof or hydrates thereof. 제 14 항에 있어서,The method of claim 14, B가 수소이고, X1및 X2가 둘다 단일 결합이고, X3이 티엔일, 티아졸일, 티아디아졸일, 이소티아졸일, 피롤일, 피리딜, 벤조푸릴, 벤즈이미다졸일, 벤조티엔일, 디벤조푸릴, 디벤조티엔일, 퀴놀일 또는 인돌일인 화합물, 그의 염 또는 이들의 수화물.B is hydrogen, X 1 and X 2 are both single bonds, X 3 is thienyl, thiazolyl, thiadiazoleyl, isothiazolyl, pyrrolyl, pyridyl, benzofuryl, benzimidazolyl, benzothienyl , Dibenzofuryl, dibenzothienyl, quinolyl or indolyl, salts thereof or hydrates thereof. 제 14 항에 있어서,The method of claim 14, X1이 페닐렌, 티오펜디일, 인돌디일 또는 옥사졸디일이고, X2가 단일 결합, -N=N-, -CH=CH-, 에틴일렌, -S- 또는 -O-이고, X3이 아릴 또는 헤테로사이클릭 기인 화합물, 그의 염 또는 이들의 수화물.X 1 is phenylene, thiophendiyl, indoldiyl or oxazoldiyl, X 2 is a single bond, -N = N-, -CH = CH-, ethynylene, -S- or -O-, X 3 A compound thereof, a salt thereof, or a hydrate thereof. 제 10 항에 있어서,The method of claim 10, 가이고, end ego, A가 옥소 기를 함유하거나 함유하지 않고, 불포화 결합을 갖거나 갖지 않는알킬렌이고;A is alkylene with or without an oxo group and with or without an unsaturated bond; B가 수소이고;B is hydrogen; R이 COOH 또는 CH2OH이고;R is COOH or CH 2 OH; X1이 단일 결합이고;X 1 is a single bond; X2가 단일 결합이고;X 2 is a single bond; X3이 치환되거나 치환되지 않은 벤조티에닐인 화합물, 그의 염 또는 이들의 수화물.A compound, a salt thereof, or a hydrate thereof, wherein X 3 is substituted or unsubstituted benzothienyl.
KR1019970709573A 1995-06-21 1996-06-19 Bicyclic amino derivatives and prostaglandin di 2 antagonists containing them KR100428601B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15457595 1995-06-21
JP95-154575 1995-06-21

Publications (2)

Publication Number Publication Date
KR19990028261A KR19990028261A (en) 1999-04-15
KR100428601B1 true KR100428601B1 (en) 2004-09-16

Family

ID=15587229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970709573A KR100428601B1 (en) 1995-06-21 1996-06-19 Bicyclic amino derivatives and prostaglandin di 2 antagonists containing them

Country Status (25)

Country Link
US (3) US6172113B1 (en)
EP (1) EP0837052B1 (en)
JP (1) JP3195361B2 (en)
KR (1) KR100428601B1 (en)
CN (1) CN1134411C (en)
AT (1) ATE337294T1 (en)
AU (1) AU714312B2 (en)
BR (1) BR9608498B1 (en)
CA (1) CA2225250C (en)
CZ (1) CZ285870B6 (en)
DE (1) DE69636478T2 (en)
DK (1) DK0837052T3 (en)
EA (1) EA000987B1 (en)
ES (1) ES2270438T3 (en)
HU (1) HUP9802678A3 (en)
IL (1) IL122332A0 (en)
IS (1) IS2359B (en)
MX (1) MX9710256A (en)
NO (1) NO975994L (en)
NZ (1) NZ310559A (en)
PL (1) PL185107B1 (en)
PT (1) PT837052E (en)
TR (1) TR199701667T2 (en)
TW (1) TW513422B (en)
WO (1) WO1997000853A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069166A (en) * 1996-12-12 2000-05-30 Shionogi & Co., Ltd. Fused heterocyclic benzenecarboxamide derivatives and PGD2 antagonists comprising them
PT944614E (en) * 1996-12-13 2003-01-31 Shionogi & Co BENZOTIOFENOCARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS THAT CONTAIN THEM
CN1122034C (en) * 1997-04-28 2003-09-24 日东电工株式会社 Optically active monomer, liquid crystalline polymer and optical element
DE69819350T2 (en) 1997-09-19 2004-07-22 Shionogi & Co., Ltd. CONNECTIONS WITH [2.2.1] BICYCLIC MOLECULE STRUCTURE
HUP0101728A3 (en) 1998-03-31 2002-04-29 Shionogi & Co 5-hydroxybenzo[b]thiophene-3-carboxylic acid and their derivatives and methods for producing them
ATE295183T1 (en) * 1998-06-03 2005-05-15 Shionogi & Co AGENTS FOR RELIEVING ITCH CONTAINING PGD2 ANTAGONISTS
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
AU1179000A (en) * 1998-11-19 2000-06-13 Shionogi & Co., Ltd. Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
DE60020226T2 (en) * 1999-03-10 2006-02-02 Shionogi & Co., Ltd. MEDICAL PREPARATIONS WITH [2.2.1] AND [3.1.1] BICYCLOSKELET THE ANTAGONISTS FOR BOTH PGD 2? AS ALSO TXA 2? RECEPTORS ARE
WO2001007423A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
EP1201238A4 (en) * 1999-07-29 2003-01-15 Ono Pharmaceutical Co Sulfonamide derivatives and remedies for allodynia
AU780790B2 (en) 1999-11-26 2005-04-14 Shionogi & Co., Ltd. NPY Y5 antagonists
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
AU2001240861B2 (en) * 2000-03-20 2006-03-30 Merck Frosst Canada Ltd Sulphonamido-substituted bridged bicycloalkyl derivatives
CA2405233A1 (en) * 2000-04-12 2001-10-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
EP1295872A4 (en) 2000-06-02 2007-05-16 Shionogi & Co Drug composition antagonistic to both pgd 2/tx a 22 receptors
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP4929472B2 (en) * 2000-08-22 2012-05-09 小野薬品工業株式会社 Carboxylic acid derivatives, methods for producing them, and agents containing them as active ingredients
CA2419722A1 (en) * 2000-09-01 2003-02-21 Masaki Asada Benzoic acid derivatives and drugs containing the same as the active ingredient
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US6693203B2 (en) * 2000-10-17 2004-02-17 Shionogi & Co., Ltd Process for the preparation of PGD2 antagonist
WO2002036583A1 (en) * 2000-11-01 2002-05-10 Shionogi & Co., Ltd. Pgd2 receptor antagonistic pharmaceutical compositions
KR100777169B1 (en) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 Medicinal preparation containing 5-methyl-1-phenyl-2-1h-pyridone as active ingredient
JP2005508172A (en) * 2001-11-07 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Methods for identifying modulators of fractalkine receptors and methods for using modulators of fractalkine receptors
AR038136A1 (en) 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
EP1558614B1 (en) 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
PL1731512T3 (en) 2004-03-05 2015-03-31 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide compound and noxious organism control agent
JP4051398B2 (en) 2004-03-11 2008-02-20 アクテリオン ファマシューティカルズ リミテッド Tetrahydropyridoindole derivatives
JPWO2006068162A1 (en) * 2004-12-24 2008-06-12 塩野義製薬株式会社 Treatment for chronic obstructive pulmonary disease
CA2601979C (en) * 2005-04-21 2014-06-17 Laboratoires Serono S.A. 2,3 substituted pyrazine sulfonamides
WO2008156573A1 (en) * 2007-06-12 2008-12-24 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
MY159870A (en) 2009-03-09 2017-02-15 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase
EA201200855A1 (en) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. CRTH2 MODULATORS
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AR088020A1 (en) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc HETEROCICLICAL COMPOUNDS AS SGC STIMULATORS
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN107266433A (en) 2010-11-09 2017-10-20 铁木医药有限公司 SGC stimulants
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
CN104066731B (en) 2011-12-27 2016-06-15 铁木医药有限公司 Can be used as the 2-benzyl of SGC stimulant, pyrazoles that 3-(pyrimidine-2-base) replaces
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
ES2774295T3 (en) 2013-03-15 2020-07-20 Cyclerion Therapeutics Inc SGC stimulators
JP2016540017A (en) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulating substance
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP2017527604A (en) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulant
CN107406422B (en) 2014-09-17 2022-02-01 赛科理音医疗有限公司 Pyrazole derivatives as sGC stimulators
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
MX2019000115A (en) 2016-07-07 2019-04-22 Ironwood Pharmaceuticals Inc Solid forms of an sgc stimulator.
MA45592A (en) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc SBS STIMULATOR PHOSPHORUS MEDICINAL PRODUCTS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561739B2 (en) 1981-12-23 1987-05-14 British Technology Group Limited Prostaglandins
US4837234A (en) 1981-12-23 1989-06-06 National Research Development Corporation Prostaglandins
US4526901A (en) * 1984-01-26 1985-07-02 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted oxamide prostaglandin analogs and their use in treating thrombolytic disease
JPS6149A (en) 1984-06-12 1986-01-06 Ono Pharmaceut Co Ltd Novel 13-aza-14-oxo-txaz analogs, their preparation and remedy for diseases caused by thromboxan, containing the same
CA1278577C (en) 1985-11-18 1991-01-02 Tatsuo Tsuri Bicyclic sulfonamide derivatives
CA1294974C (en) 1987-05-08 1992-01-28 Sanji Hagishita Bicyclic sulfonamide derivatives and process therefor
EP0312906A3 (en) * 1987-10-23 1990-09-05 Ono Pharmaceutical Co., Ltd. Novel sulfonamide derivatives
JP2565746B2 (en) * 1987-10-23 1996-12-18 小野薬品工業株式会社 New carbocyclic sulfonamide derivative
JPH0262546A (en) 1988-08-30 1990-03-02 Asahi Chem Ind Co Ltd Improved optical photosensitive resin composition
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides

Also Published As

Publication number Publication date
IS2359B (en) 2008-04-15
PT837052E (en) 2006-12-29
ES2270438T3 (en) 2007-04-01
CZ285870B6 (en) 1999-11-17
ATE337294T1 (en) 2006-09-15
EA000987B1 (en) 2000-08-28
US6384075B1 (en) 2002-05-07
AU6137096A (en) 1997-01-22
TR199701667T2 (en) 1999-10-21
BR9608498A (en) 1999-07-06
CA2225250C (en) 2005-03-22
PL324115A1 (en) 1998-05-11
NO975994L (en) 1998-02-23
US6172113B1 (en) 2001-01-09
IL122332A0 (en) 1998-04-05
AU714312B2 (en) 1999-12-23
KR19990028261A (en) 1999-04-15
DK0837052T3 (en) 2007-01-02
JP3195361B2 (en) 2001-08-06
TW513422B (en) 2002-12-11
CZ401397A3 (en) 1998-04-15
BR9608498B1 (en) 2008-11-18
EP0837052A1 (en) 1998-04-22
HUP9802678A3 (en) 1999-12-28
NO975994D0 (en) 1997-12-19
EP0837052B1 (en) 2006-08-23
EA199800074A1 (en) 1998-08-27
IS4623A (en) 1997-11-28
EP0837052A4 (en) 2001-12-19
DE69636478T2 (en) 2007-04-19
CN1134411C (en) 2004-01-14
MX9710256A (en) 1998-03-31
PL185107B1 (en) 2003-02-28
CN1193315A (en) 1998-09-16
CA2225250A1 (en) 1997-01-09
HUP9802678A2 (en) 1999-02-01
NZ310559A (en) 1999-05-28
US6498190B1 (en) 2002-12-24
WO1997000853A1 (en) 1997-01-09
DE69636478D1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
KR100428601B1 (en) Bicyclic amino derivatives and prostaglandin di 2 antagonists containing them
EP0278977B1 (en) Prodrug derivatives of carboxylic acid drugs
FI73969C (en) Process for the preparation of therapeutically active trans-4-aminomethyl cyclohexanecarboxylic acid derivatives
KR20090007571A (en) Amine derivative having npy y5 receptor antagonist activity
MX2008015768A (en) New cxcr2 inhibitors.
EP0945450A1 (en) Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same
JPH0395154A (en) (di-(tert.-butyl(hydroxy)phenylthio))-substituted hydroxamic acid derivative
EP1338594A1 (en) Pgd2 receptor antagonistic pharmaceutical compositions
JPH02196770A (en) Di-tert-butylhydroxyphenylthio derivative
US6225336B1 (en) Compounds having [2.2.1] bicyclo skeleton
PL198827B1 (en) N-ARYLSULFONYL AMINO ACID OMEGA AMIDES, method of making them, pharmaceutical agent and their application
US5338760A (en) Urea derivatives, their preparation and medicinal products containing them
JPH04230358A (en) New n-substituted derivatives of alpha-mercaptoalkylamine, process for producing same, intermediates, use theerof as medicines and compositions containing same
US5405873A (en) Substituted acetamide derivatives
JP3701878B2 (en) Bicyclocyclic amino derivatives and PGD2 antagonists containing the same
JPH02184662A (en) Glycine derivative and production thereof
WO2022246907A1 (en) Compound containing 2,4-thiazole ring, preparation method therefor, and application thereof
JPH02193965A (en) Novel 2-halogenated n-indolylethyl-sulfonamide, preparation thereof,and use thereof in drug
EP0145304B1 (en) Tetrahydro-beta-carboline derivatives and process for the preparation thereof
AU623025B2 (en) Novel sulphamoylthiophenes, a process for their preparation and their use
EP1240906A1 (en) Preventives or remedies for arrhythmia
JPH0812659A (en) Thiazole derivative and medicinal pharmaceutical preparation containing the same
JPH068275B2 (en) Phenoxyacetic acid derivative

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080411

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee